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Obesity is a rising global concern, associated with increased risk of developing 
metabolic syndrome, insulin resistance and type 2 diabetes. Chronic availability of 
excess nutrients may promote adipocyte dysfunction, especially in genetically 
susceptible individuals. Adipocyte amino acid transporter SLC7A10 and branched chain 
amino acid (BCAA) metabolism has recently been strongly associated with obesity and 
related disease, and dissection of the underlying molecular mechanisms may provide 
novel therapeutic targets. 
 
The aim of the present study was to uncover novel mechanisms linking adipocyte 
SLC7A10, BCAA uptake and catabolism, and 3-hydroxyisobutyric acid (3-HIB) release 
to adiposity, insulin resistance and T2D.  
 
In Paper 1, we performed a global transcriptome screen of adipose tissue in the context 
of obesity and insulin resistance, and identified SLC7A10 as a novel candidate gene in 
the regulation of adipocyte metabolism. We overfed Slc7a10 WT and loss-of-function 
mutant zebrafish, resulting in visceral adipocyte hypertrophy and higher weight gain for 
the mutants. Inhibition of SLC7A10 in adipocytes in vitro caused reduced serine uptake, 
total glutathione levels, insulin-dependent glucose uptake and mitochondrial respiratory 
capacity, while promoting increased ROS generation and lipid accumulation. 
Conversely, SLC7A10 overexpression showed the opposite effects on mitochondrial 
respiration and ROS compared to inhibition.  
 
In Paper 2, we found that BCAA consumption and catabolism is increased during 
adipogenesis of human as well as brown and white mouse adipocytes in vitro. 
Knockdown of the 3-HIB generating enzyme HIBCH reduced adipocyte lipid storage 
and 3-HIB release. 3-HIB treatment affected respiration and ROS generation in opposite 
directions in white and brown mouse adipocytes. 
 
In Paper 3, we performed a gene set enrichment analysis (GSEA) of RNA-sequencing 
data from SLC7A10 impaired human primary adipocytes, and found increased 





Upon SLC7A10 inhibition, adipocytes showed increased uptake of BCAAs, aspartate, 
glutamate, and increased efflux of 3-HIB.  
 
Overall, we have identified SLC7A10 and 3-HIB as regulators of adipocyte metabolism. 
Our work points to activation of adipocyte SLC7A10 as a potential preventive and/or 
therapeutic strategy for metabolic diseases, and implicates 3-HIB as a strong marker 
reflective of increased lipid accumulation, obesity and comorbidities. 
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1.1 Overweight and obesity 
1.1.1 Definition, classification, and prevalence of obesity 
Obesity is a rising health challenge worldwide and the prevalence has nearly tripled in 
the last 45 years, reaching pandemic levels. In 2016, more than 1.9 billion adults were 
defined as having overweight and 650 million of these as having obesity, which 
corresponds to 39% and 13% of the world’s adult population respectively (WHO, 2017). 
Obesity is also a major concern in Norway, and an ongoing Norwegian study named 
HUNT (Helseundersøkelsen i Nord-Trøndelag) found that the percentage of people with 
obesity in the county of Nord-Trøndelag increased from around 10% in 1986 to 21-23% 
in 2006 and 22.5-23.5% in 2018 (Krokstad et al., 2013; HUNT4 - NTNU, 2019). The 
World Health Organization (WHO) defines overweight and obesity as anomalous or 
excessive fat storage that could negatively affect health (WHO, 2017). Body mass index 
(BMI), which is calculated by a person’s body weight in kilograms divided by height in 
meters squared (kg/m2), is the most common anthropometric measure used to classify 
both overweight and obesity. A person is considered as having overweight with a BMI 
≥ 25, obesity with a BMI ≥ 30 (Garvey, 2018), and morbid obesity with a BMI ≥ 40 or 
≥ 35 with at least one obesity-related disease/comorbidity (Heymsfield and Wadden, 
2017).  
Despite being the most widely used measure of obesity, BMI has several disadvantages, 
such as failing to consider ethnicity, gender, lean mass and body fat distribution (Jackson 
et al., 2002; Nishida et al., 2004; Cornier et al., 2011). Therefore, other measures of 
obesity are also used, including waist-hip ratio (WHR), waist circumference (WC) and 
waist-height ratio, which are shown good, or better, predictors of obesity-related disease 






1.1.2 Metabolic effects of obesity 
In the context of obesity, several organs such as the adipose tissue, brain, gut, liver, 
muscles, heart and pancreas can be strongly affected by an imbalance in energy 
homeostasis. Consequently, their functions can be altered, raising the risk of disease and 
severe complications (Kim, 2016). Since the complete picture is complex and there are 
large variations between individuals, several mechanisms of disease development have 
been proposed over the years, with suggested dysfunctions in one or several of the 
tissues as primary causal events (Czech, 2020). Adipose tissue, the primary tissue 
responsible for storing excess energy as fat, is greatly expanded in obesity (Knight, 
2018; Adami et al., 2019). This may lead to dysfunctional adipocytes (See 1.2.3. 
Adipocyte dysfunction), and at first, increased sensitivity to insulin, the hormone 
regulating glucose uptake from the blood (Mehran et al., 2012). Likely, as a protective 
mechanism, local insulin resistance (IR) in adipocytes eventually occurs, which can 
further promote elevated circulating glucose levels (Ferrannini et al., 2018; Czech, 
2020). The reduced insulin response leads to increased lipolysis in adipose tissue, 
causing high circulating free fatty acid (FFA) levels, contributing to whole-body IR 
(Lusis, Attie and Reue, 2008). The brain reacts to the altered metabolic conditions by 
signaling to non-adipose tissues, affecting their metabolic functions and resulting in 
excess energy storage. Hormonal signals directly from the adipose tissue, such as leptin, 
serve to inform the brain on the status of lipid storage in adipose tissue (Das, 2010). Fat 
storage in tissues other than adipose tissue is referred to as ectopic lipid accumulation, 
and includes abnormal fat storage in the heart, skeletal muscle, pancreas and liver (Lusis, 
Attie and Reue, 2008). The latter might lead to development of diseases, such as non-
alcoholic fatty liver disease (steatosis) (Sarwar, Pierce and Koppe, 2018). After a while, 
the normal function of these tissues also becomes impaired, and to combat these 
dysfunctions, local IR occurs also here (Perry et al., 2015). Consequently, the pancreas 
increases the secretion of insulin, which initially causes a state of hyperinsulinemia. 
Eventually, as the beta cells that produce this peptide hormone no longer sufficiently 
compensate for IR, circulating glucose levels will be chronically elevated 
(hyperglycemia), which can result in type 2 diabetes (T2D) due to excessive pancreatic 





Overall, impairments of important pathways and functions in all the metabolically active 
tissues may contribute to alterations in glucose homeostasis and disease development 
(Remedi and Nichols, 2009; Cersosimo et al., 2015; Fazakerley et al., 2019). However, 
in the present thesis, the role of the adipose tissue in relation to obesity and comorbidities 
will be in focus. 
 
1.1.3 Metabolic syndrome and obesity-related diseases 
High fasting blood sugar is one of the five risk factors characterizing metabolic 
syndrome. The other four are abdominal obesity, high blood pressure, low high density 
lipoprotein (HDL) and high triacylglycerol (TAG) levels in the blood (Lusis, Attie and 
Reue, 2008). To be diagnosed with metabolic syndrome, three out of the five risk factors 
must be present (Eckel, Grundy and Zimmet, 2005). Having metabolic syndrome is 
associated with a higher risk of developing T2D, which is characterized by IR in target 
tissues and insulin deficiency due to beta cell dysfunction (Association, 2017; 
Chatterjee, Khunti and Davies, 2017). A study of 433 people with morbid obesity found 
that around 23% had impaired glycemic control or T2D, while 39.5% had metabolic 
syndrome and 72% were IR (Janković et al., 2012). In the study, an oral glucose 
tolerance test based index (clamp-like index (CLIX)) test was used, and IR was defined 
as CLIX ≤5 (Janković et al., 2012). Studies often use homeostasis model assessment-
estimated IR (HOMA-IR) to identify IR (Matthews et al., 1985), but the cutoff values 
for it to be classified as IR often vary between different studies (Qu et al., 2011). The 
gold standard for assessing IR in vivo is hyperinsulinemic-euglycemic clamp, where 
insulin levels are maintained constant by intravenous infusions of insulin (Kellar and 
Craft, 2020). Glucose is then infused, providing steady-state euglycemia, and the 
concentration of glucose taken up by all the tissues in the body can be calculated (Tam 
et al., 2012). Progressive IR is strong a predictor of future T2D (Taylor, 2012). Other 
comorbidities linked to obesity include cardiovascular disease (CVD) and many types 
of cancers (Haslam and James, 2005; Global Burden of Metabolic Risk Factors for 
Chronic Diseases Collaboration (BMI Mediated Effects) et al., 2014). 
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1.1.4 Treatment options for obesity 
Lifestyle interventions are often used to treat obesity and comorbidities, and can in some 
cases lead to stable weight loss and a reduction in risk factors for CVD (Unick et al., 
2013; Chen et al., 2015). However, studies often show a poor long-term subject 
adherence to dramatic lifestyle interventions, and bariatric surgery is currently 
considered the most effective way of treating morbid obesity and related diseases (Wing 
et al., 1998; Courcoulas et al., 2020). Bariatric surgery causes striking alterations in 
metabolism, resulting in a sustained weight loss, and often remission of T2D and 
decreased mortality (Sjöström et al., 2007). Despite these advantages, bariatric surgery 
is very invasive, expensive and might cause negative psychological and physical side-
effects, such as suicidal thoughts, alcoholism and micronutrient deficiency (Courcoulas 
et al., 2014; Kratz, 2020). Hence, this surgery is only available for people with morbid 
obesity who meet specific criteria, most commonly a BMI above 40, or above 35 
accompanied with significant morbidity (Sjöholm et al., 2013). Therefore, more 
knowledge on the specific molecular mechanisms involved in development of obesity 
and related diseases is needed to develop new and better treatment options.   
 
1.1.5 Heritability, lifestyle and epigenetics 
The primary cause of obesity is an imbalance between the total energy consumed and 
expended (WHO, 2017), but individual environmental and genetic factors regulate, 
through complex mechanisms and pathways, how the body tackles the intake of surplus 
calories (Haslam and James, 2005). Genetics can influence obesity either by a single 
mutation (monogenic obesity) or by an interplay between several loci (polygenic 
obesity), the latter being the most common genetic contributor to obesity and hence 
referred to as common (multifactorial) obesity (Heymsfield and Wadden, 2017; Rohde 
et al., 2019). Interestingly, the heritability value (h2) for body weight was found to be 
0.78-0.81 in a study of both mono- and di-zygotic twins (Stunkard, Foch and Hrubec, 
1986). h2 takes into account several genetic values, and describes the proportion of 
genetic variation based on these (Naomi R. Wray, 2008). In another twin study where 





and 0.70 for men (Stunkard et al., 1990). Additionally, Rankinen and colleagues found 
that 25-70% of the variations in BMI and total body fat composition could be explained 
by genetics (Rankinen et al., 2015). Moreover, research has identified over 870 single 
nucleotide polymorphisms (SNPs) that are strongly linked with BMI (Rohde et al., 
2019), and a study found that the heritability explained by common SNPs for BMI and 
WHR was 41% and 46%, respectively (Vattikuti, Guo and Chow, 2012). Further insight 
into the molecular mechanisms underlying this genetic contribution may enable us to 
predict an individual’s risk of obesity and related diseases, and to develop new 
prevention and treatment strategies.  
However, making the system even more complex, is the research showing that genetic 
risk can be strongly influenced by an obesogenic environment (Swinburn et al., 2011). 
Therefore, a healthy lifestyle can prevent the development of obesity and related 
diseases, even if you are genetically predisposed for obesity (Hunter, 2005). WHO 
reports that there has in recent years been an increase in the intake of energy-dense foods 
and a decrease in physical activity, causing reduced expenditure of the excess calories 
consumed, thereby driving increased obesity (WHO, 2017). The combination of genetic 
predisposition and ready access to highly processed foods that can both promote 
increased appetite (Locke et al., 2015; Hall et al., 2019) may severely challenge people 
to maintain a healthy body composition. Other lifestyle factors that are suggested to be 
linked with risk of obesity and related diseases are sleeping behaviors, socioeconomic 
status, smoking, and suboptimal intake of vitamins (Ló Pez-Sobaler et al., 2016; Justice 
et al., 2017; Wulaningsih et al., 2017). Recently, it has also been suggested that the 
influence of environmental factors on genetic predisposition might, at least in part, be 
mediated through epigenetic mechanisms in several organs, including the adipose tissue 






1.2 The Adipose tissue is more than just a fat storing unit 
1.2.1 Adipose tissue functions and cellular composition 
Adipose tissue was previously considered to be a passive tissue, with the sole purpose 
of storing energy surplus as TAG in lipid droplets. Now, adipose tissue is known to be 
an important endocrine organ, with complex and dynamic functions, ranging from 
protecting delicate organs (i.e., the eye), streamlining of aquatic mammals, providing 
insulation, and not least to regulate whole-body energy homeostasis (Pond, 1992; Rosen 
et al., 2014). When communicating with other metabolic organs, adipose tissue secretes 
cytokines, known as adipokines, existing in vast numbers with diverse functions (Deng 
and Scherer, 2010). Leptin and adiponectin were the first signaling proteins discovered 
to be secreted from adipose tissue (Zhang et al., 1994; Scherer et al., 1995). Adiponectin 
is known to decrease inflammation in several tissues and to reduce the release of glucose 
from the liver, while leptin suppresses hunger by binding the leptin receptor in the brain 
and increases the breakdown of TAG in adipocytes (Ghaben and Scherer, 2019).  
A variety of different cell types make up the adipose tissue, including immune cells such 
as macrophages and T cells, and preadipocytes and mature adipocytes (Hellman, 
Larsson and Westman, 1963; Schoettl, Fischer and Ussar, 2018). Based on the 
characteristics of the adipocytes residing in the tissue, the adipose tissue can be divided 
into three different primary groups, namely white, brown, and beige adipose tissue. 
White adipose tissue (WAT) is often thought of as the lipid storing tissue, consisting of 
unilocular cells with a single large lipid droplet and a relatively low abundance of 
mitochondria. By contrast, brown adipose tissue (BAT) is composed of multilocular 
cells with several smaller lipid droplets and a high mitochondrial content. Hence, BAT 
is a specialized energy-dissipating adipose tissue which converts chemical energy to 
heat in a process called non-shivering thermogenesis (Ghaben and Scherer, 2019). β-
adrenergic stimulation activates this process, which is driven by a mitochondrial protein 
called uncoupling protein 1 (UCP-1). UCP-1 uncouples the proton motive force of the 
respiratory chain, localized in the inner mitochondrial membrane, causing a leak of 
protons into mitochondrial matrix (Klingenspor et al., 2008). Further, this leads to the 





2014). The other type of fat cell that express appreciable levels of UCP-1 are beige 
adipocytes. These cells are interspersed among the white adipocytes and have 
characteristics that resemble both the white and brown fat cells. When stimulated by 
exercise, chronic cold exposure or β-adrenergic receptor agonists such as isoproterenol 
(ISO), UCP-1 expression, and thereby thermogenesis, is initiated in the beige cells in a 
process often called beiging (Ikeda, Maretich and Kajimura, 2018). However, recent 
lineage tracing has contributed to development of an even more complex picture of 
heterogeneity, supporting the growing evidence for distinct adipocyte subpopulations 
existing in the different adipose tissue depots (Schoettl, Fischer and Ussar, 2018; Lee et 
al., 2019; Ramirez et al., 2020; Vijay et al., 2020).  
 
1.2.2 Adipose tissue depots and expansion 
Body fat can be stored in several adipose tissue depots in the human body, largely 
divided into subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) (Lee, 
Wu and Fried, 2013). SAT is located directly below the skin, and is in humans divided 
into different compartments including abdominal, retroperitoneal, gluteal and femoral 
SAT (Schoettl, Fischer and Ussar, 2018; Kahn, Wang and Lee, 2019) (Figure 1). 
Around 80% of all human body fat is stored in subcutaneous (SC) depots (Arner, 1997). 
In mice, the main SAT depots are retroperitoneal, inter- and sub-scapular, and posterior 
adipose tissue, the latter including inguinal, gluteal and dorso-lumbal WAT. Conversely, 
the VAT surrounds and shields the organs in the trunk, and is both in humans and rodents 
divided into subtypes such as pericardial, omental (OM) and mesenteric VAT (Kahn, 
Wang and Lee, 2019) (Figure 1). In most of the adipose depots, the main cell type is 
white adipocytes, but there are also some depots rich in BAT (Schoettl, Fischer and 
Ussar, 2018). Previously, human BAT was thought to only exists in the interscapular 
depot of infants but to be lost in adults. However, in 2009, independent studies reported 
that several adipose depots contain brown adipocytes in adults, such as those in the neck, 
supraclavicular and paravertebral regions (Cypess et al., 2009; van Marken Lichtenbelt 
et al., 2009; Virtanen et al., 2009). Rodents have BAT in cervical, axillary and inter- 
and subscapular depots (Adipose Tissue and Adipokines in Health and Disease, 2007; 
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de Jong et al., 2015) (Figure 1). On the contrary, zebrafish is thought to have no BAT, 
but adult fish have several anatomical sites containing WAT, including the cranium, 
esophagus, mandible, around the eyes, among the pancreatic cells, and SAT (the latter 
is illustrated in Figure 1). Zebrafish also have white adipocytes in VAT, which is for 
example located behind the swim bladder and by the visceral cavity (Figure 1) (Imrie 
and Sadler, 2010). 
 
Figure 1. Adipose tissue depots in human, mouse and zebrafish. The location of several of the human and 
mouse adipose tissue depots are depicted in this figure, including epicardial and pericardial and retroperitoneal 
depots. In the human picture, perirenal, abdominal, mesenteric, and omental depot locations are all illustrated 
separately, while they are visualized together for the mouse. Gluteal and femoral location is depicted exclusively 
in the human figure, and interscapular, subscapular, axillary and posterior for mouse. Only the main zebrafish 
visceral and SC adipose tissues are visualized here. SAT depots are illustrated in yellow and visceral adipose tissue 
depots in green. This figure is based on (Imrie and Sadler, 2010), (Quail and Dannenberg, 2019) and (Schoettl, 
Fischer and Ussar, 2018).  
                          
             
           
         
         
          
       
       
       
               
         
        
                      





For a long time now, it has been known that SAT and VAT distribution in humans is 
largely dependent on variables such as age and sex (Enzi et al., 1986). Women typically 
have a higher fat storage in femoral and gluteal SAT than men, which is correlated with 
a healthier metabolic phenotype, compared to storing fat in the intra-abdominal region 
(Karastergiou et al., 2012; Karpe and Pinnick, 2015). In men, VAT accounts for about 
10-20% of the total fat mass, while it makes up only 5-8% in women (Wajchenberg, 
2000). Moreover, VAT mass increases in both genders with increasing age (Ibrahim, 
2010), concomitant with a higher risk of developing IR and metabolic diseases (Chen et 
al., 2018). 
How fat is stored in the different adipose depots might also affect disease risk. In 
conditions of excess nutrient availability, the adipose tissue is capable of expanding in 
two different ways, namely by hyperplasia or hypertrophy. Hyperplasia denotes when 
adipose tissue expands by increasing the number of adipocytes, and this process may 
represent a healthier way of storing surplus energy, compared to hypertrophy, which 
results from storing TAG in already existing adipocytes (Longo et al., 2019). The final 
number of adipocytes may largely be decided during childhood and stays constant in 
both lean and obese adults, and 10% of fat cells are renewed each year (Spalding et al., 
2008). However, both obesity in early childhood and overfeeding later in life is 
associated with increased hyperplasia in specific adipose depots in adults (Tchoukalova 
et al., 2010), and hyperplasia has been called a recovery mechanism responding to 
overnutrition (Longo et al., 2019). Interestingly, studies in adult mice have shown that 
VAT has the ability to expand through both hyperplasia and hypertrophy, while SAT 
expands mainly through hypertrophy (Wang et al., 2013; Kim et al., 2014; Jeffery et al., 
2015). Hypertrophy is characterized by large lipid-laden adipocytes, which is found to 







1.2.3 Adipocyte dysfunction 
When adipocytes increase rapidly in size due to a high energy storing demand in obesity, 
the extracellular matrix (ECM), providing the structural foundation of the adipose tissue, 
is remodeled to support the adipose tissue’s growing mass (Mariman and Wang, 2010). 
This remodeling is associated with several alterations in adipocyte metabolism (Ghaben 
and Scherer, 2019). For instance, hypertrophy may increase mechanical stress on the 
adipocytes, causing fibrosis and hypoxia, the latter due to reduced oxygen availability 
for each adipocyte in the growing adipose tissue (Halberg et al., 2009; Khan et al., 
2009). These stressors might also increase lipogenesis and induce inflammation in the 
adipose tissue, further causing cellular changes leading to secretion of inflammatory 
signaling proteins such as tumor necrosis factor (TNF) or reduce production of anti-
inflammatory adipokines, which are both events associated with IR (Klöting et al., 2010; 
Ghaben and Scherer, 2019). In addition, the high demand to sequester lipids in the 
adipocytes may also cause mitochondrial dysfunction upon nutrient excess, and limited 
oxidative phosphorylation in murine fat cells has been described as a hallmark of obesity 
(Schöttl et al., 2015). Adipocyte lipid accumulation is also linked to reactive oxygen 
species (ROS) levels, and while normal levels might regulate adipogenesis, too high or 
low ROS levels are thought to impair adipocyte function (Jankovic et al., 2015; Ghaben 
and Scherer, 2019; Longo et al., 2019). 
 
1.2.4 Adipogenesis  
When adipose tissue expands via hyperplasia, multipotent mesenchymal stem cells 
undergo adipogenesis to become mature adipocytes. This process of adipocyte 
differentiation, named adipogenesis, is divided into two steps. Most of the previous 
research is performed on the second phase in vitro, and we know little about the exact 
molecular mechanisms in vivo (Ghaben and Scherer, 2019). Briefly, the first phase is 
the commitment phase, where the fibroblast-like cell becomes restricted to the adipocyte 
fate without any changes in morphology. This is dependent on zinc-finger transcription 
proteins and bone morphogenic proteins (BMPs) that activate production of other 





second phase (Huang et al., 2009; Gupta et al., 2010; Quach et al., 2011). Several 
pathways, such as the wingless-type mouse mammary tumor virus integration site 
family (WNT)/β-Catenin pathway, also need to be inhibited before the cells can commit 
to the adipocyte linage (Longo et al., 2019). In the second step, the newly formed 
preadipocyte undergoes terminal differentiation. Firstly, SMAD4 activates transcription 
of the adipogenesis master regulator peroxisome proliferator-activated receptor-γ 
(PPARγ) (Ghaben and Scherer, 2019). Physiological ligands of this master TF with high 
affinity are not known, although several ligands with relatively low abundance or 
affinity are suggested, including long-chain polyunsaturated fatty acids (FAs) (Schupp 
and Lazar, 2010). There are several synthetic drugs called thiazolidinediones (TZDs) 
that are agonists of PPARγ, and they are used for activation both in vitro and in vivo 
(Rosen et al., 1999). When activated, PPARγ induces expression of co-activator 
CCAAT/enhancer-binding protein-α (C/EBPα), which together with PPARγ trigger 
expression of other proteins important for the function of mature adipocytes, such as 
adipokines and proteins involved in insulin and lipid metabolism (Lefterova et al., 
2008).  
 
1.2.5 Lipolysis, glucose uptake, lipogenesis and glyceroneogenesis 
TAG molecules stored in lipid droplets in mature adipocytes are hydrolyzed into a 
glycerol molecule and three FAs when the body enters a state of fasting and thus needs 
energy to fuel vital functions. This process is called lipolysis. The glycerol and FFAs 
can then be released from the adipocytes and transported to other organs (e.g. myocytes) 
via the bloodstream, where FFAs can be broken down by β-oxidation and used to fuel 
the tricarboxylic acid (TCA) cycle in the mitochondria of liver or muscles (Yu and 
Ginsberg, 2005). Secreted lipolytic intermediates and products are also important in 
cellular signaling with other tissues (Zechner et al., 2012). In addition, the FAs from 
adipocyte lipolysis can be converted to Acyl-Coenzyme A (CoA) in the fat cells, and 
enter β-oxidation in the mitochondria (Hankir and Klingenspor, 2018). β-oxidation 
however, mostly occurs in BAT to fuel thermogenesis, but it might also occur in WAT 
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during fasting or to induce beiging (Wang et al., 2003; Lee, Ellis and Wolfgang, 2015; 
Gonzalez-Hurtado et al., 2018).  
 
 
Figure 2. Basic overview of de novo lipogenesis, TCA cycle and glyceroneogenesis. Selected key enzymes are 
shown in blue/bold. The yellow square indicates processes in mitochondria. The figure is based on (Jitrapakdee, 
Vidal-Puig and Wallace, 2006).  
 
Compared to BAT, WAT is more specialized towards storing excess nutrients as lipids 
to provide the body with energy when it needs it. This process is called lipogenesis, 
involving both de novo synthesis of FAs from precursors such as glucose and amino 
acids, and TAG synthesis where three FFAs are esterified to one molecule of glycerol-
3-phosphate (G-3-P), forming one TAG molecule (Reshef et al., 2003) (Figure 2). In 
adipocytes, FFA can be taken up from the circulation or be synthesized de novo from 
substrates such as glucose or branched chain amino acids (BCAAs) through acetyl-
coenzyme A (Acetyl-CoA) and pyruvate (Reshef et al., 2003; Crown, Marze and 
Antoniewicz, 2015; Green et al., 2015; Ladeira et al., 2016). G-3-P is either produced 
from glucose, or in the metabolic pathway glyceroneogenesis (Nye et al., 2008). 





that insulin is needed to induce the translocation of glucose trasporter-4 (GLUT4) from 
vesicles inside the adipocytes to the plasma membrane (Cushmans and Wardzalafj, 
1980). Adipocyte GLUT4 is important to maintain whole-body glucose homeostasis 
(Abel et al., 2001), and the glucose taken up into the adipocyte is used to fuel branches 
of glycolysis, the TCA cycle and pyruvate anaplerosis (Krycer et al., 2017). The latter 
is a process where pyruvate is converted to oxaloacetate by pyruvate carboxylase (PC), 
and in adipocytes this enzyme is important for both the de novo FA synthesis and 
glyceroneogenesis (Jitrapakdee, Vidal-Puig and Wallace, 2006) (Figure 2). Another 
enzyme essential for glyceroneogenesis is PEPCK, which converts oxaloacetate to 
phosphoenolpyruvate (PEP) (Figure 2). Glyceroneogenesis has emerged as a major 
source of carbon for glycerol, and is now thought to be more important than glucose for 
this process in adipocytes (Nye, Hanson and Kalhan, 2008). The precursors that can be 
used to synthesize glycerol in this pathway are many, including TCA intermediates, 
pyruvate, lactate and certain amino acids (Ballard, Hanson and Leveille, 1967; Reshef, 
Niv and Shapiro, 1967; Reshef, Hanson and Ballard, 1969).  
 
1.3 Alanine, serine, cysteine-transporter 1 (SLC7A10)  
1.3.1 SLC7A10 in metabolic diseases and adipocytes 
Several amino acid transporters have recently been implicated in the development of 
human disease (Kandasamy et al., 2018). Among these is the small neutral amino acid 
transporter SLC7A10 (solute carrier family 7 member 10), also named Asc-1 (Alanine 
serine cysteine transporter 1), which has previously been associated to T2D risk (Small 
et al., 2011). Small et al. studied a T2D-associated SNP by the KLF14 gene, which 
appears to modulate the expression of this maternally expressed TF (Small et al., 2011). 
This SNP was previously found to be associated with T2D risk (Voight et al., 2010), 
and Small et al. suggested that KLF14 (Krüppel-like Factor 14) acts as a master trans-
regulator of gene expression in SAT. Interestingly, in a cohort of 776 female twins, 
SLC7A10 was the only gene that was down-regulated in SAT of people carrying this 
T2D diabetes associated risk allele, and showed the strongest heritable expression with 
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a h2 of 0.79. In addition, SLC7A10 expression was found to correlate negatively with 
metabolic traits such as BMI, HOMA-IR and circulating TAG levels, and positively 
with circulating HDL and adiponectin levels (Small et al., 2011). In 2018, Small and 
coworkers implicated KLF14 T2D risk alleles in the regulation of female-specific body 
fat distribution and adipocyte size (Small et al., 2018). Moreover, SLC7A10 has been 
found to serve as a cell surface marker of white adipocytes, with an expression ranging 
from 4-fold higher in mesenteric WAT than in interscapular BAT, to 79-fold higher in 
perigonadal WAT compared to subscapular BAT. In addition, the expression of 
SLC7A10 is 5-fold higher in WAT compared to any region of the brain, where this 
carrier has received a lot of attention due to its relatively high expression and its neutral 
amino acid transporting functions (Ussar et al., 2014).  
 
1.3.2 SLC7A10 transports small neutral amino acids  
SLC7A10 is a sodium-independent amino acid transporter, localized in the plasma 
membrane, carrying small neutral amino acids such as serine, glycine, alanine, 
threonine, and cysteine. The transporter can transport both the L- and D-stereoisomers 
of these amino acids (Fukasawa et al., 2000), but exhibits a higher affinity for the 
glycine, L-serine, D-serine and D-alanine (Nakauchi et al., 2000). Moreover, SLC7A10 
is a member of the SLC7 family of amino acid carriers, which consists of two subgroups, 
namely the cationic amino acid transporters (CATs) and the heterodimeric amino acid 
transporters (HATs) (Verrey et al., 2004). Since SLC7A10 is linked to the glycoprotein 
(heavy chain) 4F2hc (SLC3A2) through a highly conserved disulphide bridge, which is 
required for the carrier to function, it is defined as a HAT (Fukasawa et al., 2000; 
Nakauchi et al., 2000). A trait that makes SLC7A10 unique among amino acid 
transporters, is its two different mechanisms of action. The main mechanism is exchange 
mode, where the carrier mediates bidirectional transport of amino acids coupled with 
transport of small neutral amino acids in the other direction, making it an antiporter 
(Fukasawa et al., 2000). In addition, amino acids can be transported via facilitated 





spontaneously move along their concentration gradient through SLC7A10 (Fukasawa et 
al., 2000; Pineda et al., 2004).  
Glycine and D-serine have particularly received attention in studies of SLC7A10’s roles 
in the brain, due to their functions as positive allosteric modulators of a variant of 
glutamate receptors entitled N-methyl-D-aspartate (NMDA) receptor (Rutter et al., 
2007). The NMDA receptor is linked to memory loss and to various disorders such as 
Alzheimer and schizophrenia, and SLC7A10 function in the brain has therefore been the 
focus of investigation (Fukasawa et al., 2000; Helboe et al., 2003; Matsuo et al., 2004; 
Pineda et al., 2004; Xie et al., 2005; Burnet et al., 2008; Rosenberg et al., 2013; Safory 
et al., 2015; Ehmsen et al., 2016; Billard and Freret, 2018; Mesuret et al., 2018). Hence, 
several inhibitors of SLC7A10 have been developed over the last 20 years, including 
ACPP (Sakimura et al., 2016), BMS-466442 (BMS) (Brown et al., 2014) and Lu 
AE00527 (LU) (Sason et al., 2016), and their mechanisms and specificity have been 
thoroughly examined (Kutchukian et al., 2017; Torrecillas et al., 2019; Mikou et al., 
2020). Previous studies in non-adipose tissue have shown that SLC7A10 can transport 
both D- and L-serine, but directionality of the transport has been uncertain (Matsuo et 
al., 2004; Rutter et al., 2007; Safory et al., 2015; Sakimura et al., 2016; Sason et al., 
2016). Indeed, to this date, the preferred direction of amino acid transport through 
SLC7A10 in the brain in vivo is not yet resolved (Mikou et al., 2020), and to our 
knowledge nothing was known about this transporter’s direct and indirect functions in 
adipose tissue before the present project.  
 
1.4 Amino Acids: Protein building blocks and beyond 
1.4.1 Amino acid properties and functions 
Amino acids consist of an amino group and a carboxyl group, and there are 20 different 
proteogenic naturally occurring amino acids, divided into essential and non-essential 
(Wu, 2013). The essential amino acids are only available in food, while the non-essential 
can be produced in the body from other amino acids or metabolites (Salazar, Keusgen 
and von Hagen, 2016). Previously, amino acids were only thought of as basic building 
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blocks used in protein translation. However, we now know that amino acids are also 
important for processes such as lipid metabolism, purine synthesis, biosynthesis of 
biomolecules and fueling of energy metabolism (Wu, 2010; Saha et al., 2014).  
Different amino acids have different entry points into the metabolic pathways. For 
example, aspartate and asparagine can be converted to oxaloacetate, a central 
intermediate of the TCA cycle, while the end products of BCAA degradation can be 
both propionyl-CoA and acetyl-CoA. Alanine, cysteine, threonine, tryptophan, glycine 
and serine are precursors of pyruvate, and glutamine, proline, arginine and histidine can 
all be converted to glutamate, which is a direct precursor of the TCA intermediate α-
ketoglutarate (α-KG) (Berg, Tymoczko and Stryer, 2002). In addition to fueling 
metabolism, a recent study found that amino acids are more important than glucose for 
providing carbon for cell proliferation in mammalian cells (Hosios et al., 2016). Due to 
the amino acids’ many important cellular functions, their circulating levels and 
metabolic potential in various tissues have been linked to various diseases, including 
obesity and comorbidities (Felig, Marliss and Cahill, 1969; Drábková et al., 2014; 
Martínez et al., 2017; Gar et al., 2018; Nie et al., 2018).  
 
1.4.2 One-carbon metabolism and disease 
Both serine and glycine, which are known to have a high affinity for the amino acid 
transporter SLC7A10 in the brain ((Fukasawa et al., 2000; Nakauchi et al., 2000)), have 
central roles in one-carbon metabolism, where carbon units are circulated through the 
folate and methionine cycle (Matsuo et al., 2004; Yang and Vousden, 2016). These 
cycles regulate several pathways and mechanisms, through biosynthesis of molecules 
such as lipids, nucleotides, proteins and substrates for methylation reactions, and 
through regeneration of functional metabolites important for maintenance of biological 
processes (Locasale, 2013; Maddocks et al., 2016). 
Closely coupled to the methionine cycle is the transsulfuration pathway, where serine, 
glycine and cysteine serve as key precursor for glutathione (GSH), the body’s major 





carbon metabolism, serine is particularly important for cellular respiration in 
mammalian cells (Lucas et al., 2018), generation of ATP, and lipid metabolism 
(Vazquez, Markert and Oltvai, 2011; Tedeschi et al., 2013; Gao et al., 2018). Due to its 
regulatory function in many metabolic pathways and processes, altered or dysregulated 
one-carbon metabolism is implicated in several diseases such as CVD, Alzheimer and 
cancer (Ducker and Rabinowitz, 2017). Furthermore, serine consumption and 
metabolism has been implicated in the development of cancer, in part because of its role 
in fueling cell proliferation (Labuschagne et al., 2014; Newman and Maddocks, 2017a), 
and has also been linked to non-alcoholic fatty liver disease (Mardinoglu et al., 2014).  
 
1.4.3 BCAAs in obesity, insulin resistance disease and adipocyte metabolism 
The BCAAs, leucine, valine and isoleucine, have been at the center of attention in the 
past several years, partly due to observations that high BCAA plasma levels show a 
strong positive association with obesity and IR (Felig, Marliss and Cahill, 1969; 
McCormack et al., 2013). In addition, there is now emerging evidence implicating 
defects in BCAA catabolism in the pathogenesis of metabolic diseases and metabolic 
syndrome (Zhou et al., 2019), and in impairments in specific energy metabolic 
processes, such as mitochondrial respiration and glycolysis (Wang et al., 2019).  
Valine, isoleucine and leucine are all essential amino acids and there are over 40 
mitochondrial enzymes responsible for their catabolism in mammals (Lynch and 
Adams, 2014). The first enzyme in the catabolic pathway is the branched-chain amino-
transferase (BCAT), generating branched-chain keto acids BCKAs (Hutson, Sweatt and 
LaNoue, 2005), alpha keto isocaproate  (from leucine), alpha keto methyl valerate (from 
isoleucine) and alpha keto isovalerate (from valine) (Figure 3) (Arany and Neinast, 
2018). Subsequently, BCKA dehydrogenases (BCKDs) irreversibly decarboxylate the 
BCKAs, forming branched chain acyl-coenzyme As (CoAs) in a rate limiting step 
(Neinast, Murashige and Arany, 2019). Isoleucine catabolites are further metabolized 
through several steps into Acetyl-CoA, while leucine catabolites can also be used to 
form propionyl-CoA (Adeva-Andany et al., 2017). Valine, on the other hand, has an 
additional fate. The enzyme hydroxyisobutyryl-CoA hydrolase (HIBCH), which is 
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responsible for removing the CoA moiety from 3-hydroxyisobutyryl-CoA, renders the 
3-hydroxyisobutyric acid (3-HIB) free to either leave the cell or to be catabolized further 
to methylmalonate semialdehyde (MMS) (J. Letto, Brosnan and Brosnan, 1986; 
Taniguchi et al., 1996). The latter can be used in pyrimidine metabolism, or be converted 
to propionyl-CoA or methylmalonyl-CoA (MMA), and be utilized in the synthesis of 
odd chain FAs or cholesterol, or fed into the TCA cycle (J Letto, Brosnan and Brosnan, 
1986; Molloy et al., 2016).  
 
Figure 3. General overview of BCAA catabolism. This figure is based on (Neinast, Murashige and Arany, 2019) 
and (KEGG PATHWAY: Valine, leucine and isoleucine degradation - Reference pathway, 2020). 
 
Interestingly, elevated circulating 3-HIB levels have recently been associated with IR, 
T2D and gestational diabetes (Harris et al., 2017; Haufe et al., 2017; Andersson-Hall et 
al., 2018; Mardinoglu et al., 2018). Several organs may contribute to the accumulation 
of BCAAs and 3-HIB observed in the blood related to obesity and metabolic syndrome, 
including the liver, heart, skeletal muscles, and adipose tissue (Kedishvili et al., 1994; 
Lynch and Adams, 2014; Lyon et al., 2019). Knowledge is lacking on how the complex 





which tissues have the metabolically strongest influence on disease pathogenesis. 
However, adipose tissue is emerging as a promising candidate, with a high basal uptake 
of the BCAAs, and impairments in BCAA catabolism in the context of obesity and 
comorbidities (Lackey et al., 2013; Badoud et al., 2014; Burrill et al., 2015; Blanchard 
et al., 2018). During adipogenesis, fat cells switch from using glutamine and glucose as 
primary substrates for Acetyl-CoA synthesis to utilizing more BCAAs, and impairment 
of BCAA catabolism has been shown to perturb adipogenesis (Green et al., 2015). 
Moreover, the BCAAs provide carbons to generate FAs in white adipocytes (Crown, 
Marze and Antoniewicz, 2015), and a recent study found that the BCAAs are transported 
at a higher rate into the mitochondria of brown adipocytes that are exposed to cold-
stimulus, thereby reducing the circulating BCAA levels and exerting an improved 
regulatory effect on energy homeostasis (Yoneshiro et al., 2019). Yet, little is known 
about the differences between BCAA metabolism in WAT and BAT, and whether 
adipocytes secrete 3-HIB. It was previously shown that 3-HIB stimulates uptake of FAs 
from endothelial cells connected to muscle tissue, dependent on the PPARγ coactivator 
PGC-1α (Jang et al., 2016). However, it is not known if this valine catabolite can also 
modulate adipocyte biology.  
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2. Aims of the study 
The overall aim of the study was to expand our knowledge of the role of adipocyte 
SLC7A10 and amino acid metabolism in obesity.  
Specific objectives were to:  
1. Uncover novel functions of SLC7A10 in adipocytes.  
2. Delineate mechanisms by which impairment of SLC7A10 might lead to obesity, 
adipocyte hypertrophy and IR. 
3. Determine the association between circulating BCAAs and 3-HIB with obesity, IR 
and T2D, and how BCAA catabolism and 3-HIB are linked to adipocyte biology, 
including comparison of adipocyte subtypes. 
4. Identify specific pathways and substrates involved in SLC7A10-dependent 
triacylglycerol storage in adipocytes and assess how SLC7A10 relates to amino acid 






3. Methodological considerations 
The present work was based on data from different sources, including human cohorts, 
animal studies, and in vitro cultured human and mouse primary adipocytes, as well as 
immortalized murine cell cultures. Consistent results across these data sources has given 
a sound foundation on which to draw conclusions. Nonetheless, each of these sources 
of data has limitations that need to be carefully considered. Materials and methods used 
in this thesis are described in full in the methods section of each paper, while key models, 
assays and analyses are briefly presented and discussed below.  
 
3.1 Clinical cohorts  
Together with collaborators from different parts of the world, we have analyzed several 
human cohorts for the papers presented in this thesis. All studies were approved by the 
respective Regional Ethical Committees, and all participants gave written informed 
consent. Seven, three and one cohorts were used in Paper 1, 2 and 3, respectively. All 
the anthropometric data for the different cohorts are described in detail in the papers.  
There are many strengths of using several human cohorts, including that the data from 
clinical cohorts reflect the current state of the organs and tissues in the body, which can 
be linked to the development of multiple diseases. Cohort data may therefore expose a 
higher clinical relevance compared to experiments performed in in vitro cell cultures 
and can be valuable as a starting point to systematically find candidate genes or 
biomarkers involved in human disease. For example, from the ADIPO cohort (Paper 1) 
we have obtained clinical information and RNA expression data from both stromal 
vascular fraction (SVF) and mature adipocytes isolated from different adipocyte depots 
of the study participants as described previously (Veum et al., 2012). This gave us the 
opportunity to examine differences in gene expression between adipose depots, between 
SVF and adipose tissue, and between different people, which lead to the discovery of 
several candidate genes involved in metabolic syndrome, such as SLC7A10. Using 
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several different cohorts also serve to validate findings and support more robust 
conclusions. 
Some of the analyses from our human cohorts are based on co- and anti-expression, or 
correlations between gene expression, various traits of metabolic syndrome and adipose 
tissue volume or adipocyte size. Therefore, it is important to distinguish association and 
co-expression from causality. Thus, conclusions of whether increased SLC7A10 
expression contributes causally to reduced body weight and health improvements 
observed after bariatric surgery, or if it is a consequence of these changes, cannot be 
determined from these data alone. The same is also true for the associations observed 
between the plasma 3-HIB levels, and various metabolic risk factors and the glycemic 
status of the individual. Therefore, animal models with impairments in the function of 
the target protein or enzyme of interest, herein SLC7A10 and HIBCH, are pivotal for 
uncovering the biological processes involved, and whether these are important causal 
contributors in the development of obesity and related diseases. 
 
3.2 Slc7a10b loss-of-function Zebrafish (Paper 1)  
The overfeeding experiment in Slc7a10b loss-of-function zebrafish presented in this 
thesis was conducted at the Institute of Marine research (former NIFES). The Norwegian 
Food Safety Authority authorized experiments performed later than 5 days post 
fertilization (dpf) (FOTS ID 9199). The fish were raised and cared for in accordance 
with the guidelines of the Norwegian Animal Welfare Act, and the ethical principles of 
replacement, reduction and refinement (The Three Rs) were applied.  
Homozygote wild type (WT) and Slc7a10b mutant (sa15382) zebrafish were bred from 
heterozygote eggs obtained from the Zebrafish International Resource Center. The 
mutant fish contain A→T point mutation in the conserved 3’ splice site between exon 6 
and 7 in the Slc7a10 isoform b gene (ENSDART00000073398.5), causing a disruption 
in the splice site, prohibiting the removal of the intron in the mature mRNA. 





either rendered inactive or directly sent to degradation after translation due to impaired 
protein folding.  
When performing animal experiments, it is important to limit possible stress factors. 
Towards this end, the adult zebrafish were housed in 1.5 or 3-liter tanks with a standard 
recirculating system, daily water exchange and electrical conductivity. In addition, the 
fish were kept in a 14h light/10h dark cycle, and fed with a complete nutrition product 
at 8am, noon and 4pm. The zebrafish were also fed freshly hatched Artemia one time 
per day, to ensure welfare and an enhanced diet variation. 
During the overfeeding study, 3 fish were held per tank and the circulation system was 
shut down 5 minutes prior to and 30 minutes after feeding, to maintain a better control 
of the food intake. Importantly, before conducting the main overfeeding study, we 
performed a two-week pilot study in 6 WT and 6 loss-of-function 2-month old zebrafish, 
revealing a large variation in body weight between male and female zebrafish, most 
likely due to the production of eggs in the females. Thus, to limit variations in body 
weight and size, the final overfeeding study was performed using only male fish. The 
main 8-week overfeeding study was performed in 33 WT and 39 mutant 4-month old 
zebrafish, and length of each fish was recorded at the start and the end of the study, 
while weight was measured at the start and after 3, 6 and 8 weeks. Each tank held 3 fish, 
to improve their quality of life, and to limit the use of bench space and tanks. In addition, 
power calculations suggested that this number of tanks (and fish) would be sufficient 
(discussed further below).  
Moreover, we learned that collecting blood from tiny fish such as zebrafish is often quite 
challenging, and several different methods exists. We ended up with performing a 
collection method modified from a previous study, where the tail fin of each fish was 
cut directly after sacrifice, and each fish was put into an Eppendorf tube containing 
ethylenediamine tetra acetic acid (EDTA) solution and spun in a centrifuge to use the 
centrifugal force to extract the blood into the bottom of the tube. Using heparin or EDTA 
coated tubes might have resulted in better quality of the collected blood, and/or less 
coagulation of blood on the tailfin of the fish. The use of more anticoagulant could 
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therefore have increased the volume of plasma obtained from each fish, and enabled 
more analyses, such as measuring metabolite and amino acid plasma levels. 
Unfortunately, we did not have sufficient blood to measure some of the key circulating 
parameters that are linked to obesity and T2D, and could not properly assess, e.g., the 
degree of whole-body IR in our WT and mutant zebrafish. 
Recently, zebrafish have emerged as a valuable model for investigating adipose tissue 
biology, including glucose homeostasis and lipid metabolism (Zang, Maddison and 
Chen, 2018), as well as other mechanisms involved in the pathogenesis of metabolic 
diseases (Oka et al., 2010; Schlegel and Gut, 2015), including NAFDL (Non-alcoholic 
fatty liver disease), IR and T2D (Zang, Shimada and Nishimura, 2017; Chen, Zheng and 
Zhang, 2018). It has frequently been used as a model for diet-induced obesity (Ran et 
al., 2017) and recently also as a model to study effects of aging on mitochondrial 
respiration capacity (Salmi, Tan and Cox, 2019). In addition, it is important to note that 
zebrafish are thought to not possess any thermogenic beige or brown adipocytes, and 
they can therefore be a useful model organisms for studying effects of genetic 
modifications on exclusively WAT metabolism and function (Gesta, Tseng and Kahn, 
2007; Seth, Stemple and Barroso, 2013). This is especially important in the context of 
SLC7A10, which was previously identified as a marker for white and not beige or brown 
adipocytes (Ussar et al., 2014). 
All teleostean fish, such as zebrafish, originate from a lineage that went through a whole 
genome duplication 250 million years ago. Thus, there might be several versions of the 
same gene in one species (Amores et al., 1998; Jatllon et al., 2004; Voldoire et al., 
2017). These genes are called paralogs, and usually develop different functions. 
Orthologs on the other hand, are genes in different species evolved from a common 
ancestral gene, and more often retain the same function (Stamboulian et al., 2020). 
Whereas humans and mice express a single isoform of SLC7A10 exhibiting 93% protein 
sequence identity (Nakauchi et al., 2000), zebrafish express two paralogs, Slc7a10a and 
Slc7a10b, showing 74% and 76% sequence identity with human SLC7A10, respectively 
(T coffee alignment tool). To further assess similarity of the functional SLC7A10 





(SSPs) for the human, mouse and zebrafish orthologous SLC7A10 proteins using the 
software HMMTOP, and combined these results with our multiple sequence alignment 
(MSA) (Jersin, 2016) (Figure 4). SLC7A10 belongs to the APC superfamily of 
transporters, which prompted us to utilize HMMTOP, since this software has previously 
been shown to reliably predict the secondary structure of transmembrane proteins 
(Reddy et al., 2014). Our MSA showed cross-species conservation of a large proportion 
of the amino acid residues, with 333 residues (around 64%) fully conserved the four 
species. All predicted secondary structures were in the same regions of the protein 
sequences of all species, thereof 12 transmembrane helices (Jersin, 2016) (Figure 4). 
This similarity supports the functional relevance of our zebrafish as a partial Slc7a10 
knockout model.  
 
Figure 4. Mouse, zebrafish and human SLC7A10 are all predicted to have 12 transmembrane 
helixes located in the same regions of the protein sequence. To generate a multiple sequence 
alignment (MSA) of human, mouse and zebrafish Slc7a10 protein sequences we utilized the T-coffee 
alignment tool. Subsequently, secondary structure predictions (SSPs) were performed separately for all 
species using the HMMTOP tool, identifying 12 transmembrane helixes (black squares around the one 
letter code for the amino acids). The intracellular side of the cell membrane is indicated by a thick green 
line, and the extracellular side with a thick yellow line. Conservation of amino acids between the 
orthologs is indicated with the following symbols: *, fully conserved residue; :, conserved groups with 
strong similar properties; ., conserved groups with weak similar properties. This MSA was also 
presented in the Master Thesis “Novel functions of the amino acid transporter SLC7A10 in adipocytes” 
(Jersin, 2016).  
38 
 
Of note, our zebrafish study includes no measurements of energy expenditure or direct 
food intake. However, no differences between tanks were observed by a blinded lab 
technician, and all the food was consumed by the three fish in each tank (independent 
of the genotype) before the circulation system was turned back on. It is also worth noting 
that the loss-of-function of Slc7a10b in Zebrafish was global and not adipose tissue 
specific. Thus, we cannot conclude to what extent the obesity phenotype in the mutant 
zebrafish depended on effects in other less Slc7a10-enriched tissues, such as the brain, 
and the pathogenic relevance of impaired Slc7a10 function in an adipose-specific 
knockout animal model would be of great value (further discussed in 7. Future 
Perspectives). On the other hand, a study showed that homozygote Slc7a10 mutant mice 
showed tremors, seizures, early postnatal death and 20-30% less body weight 14 days 
after birth compared to their WT counterparts (Xie et al., 2005). In addition, another 
study directly injected Slc7a10 inhibitor LU, which cannot cross the blood-brain barrier, 
into the brain of mice and observed no difference in body weight compared to vehicle 
(Sason et al., 2016). Due to the function and expression of Slc7a10 in the brain, other 
researchers have performed several studies with suppression of Slc7a10 expression and 
function in this tissue. However, none of these studies have to our knowledge reported 
increased weight gain compared to control, suggesting that the effects we observed in 
our zebrafish study were largely due to lack of Slc7a10 function in peripheral tissues 
(e.g., adipose tissue). A mouse or zebrafish study with animals harboring an adipose 
specific knockout is therefore warranted, but in vitro target tissue cell models can also 
be very helpful tools to examine effects and specific mechanistic pathways affected by 
modulation of target protein function and expression. Herein, we have modulated 
SLC7A10 by pharmacological inhibition and overexpression, and HIBCH by 
knockdown (KD), using cultured human and mouse adipocytes as our model systems.   
 
3.3 Human primary adipocytes, and mouse and human cell cultures 
All the adipose tissue samples utilized in this thesis were taken with approval from the 





consent. For the current projects, we have in total isolated human primary adipocytes 
from abdominal subcutaneous liposuction material collected from around 40 patients at 
Aleris or Plastikkirurg1 in Bergen, Norway. Briefly, we enzymatically digested the 
adipose tissue, isolating the stromal vascular fraction (SVF) containing preadipocytes 
as described previously (Stenson et al., 2011; Lee and Fried, 2014) and seeded cells 
directly into cell culture plates. We also obtained immortalized human cells from Joslin 
Diabetes Center (Harvard Medical School, Boston, USA), isolated from SC neck 
adipose tissue of a subject undergoing thyroidectomy (Cypess et al., 2013). In addition, 
perirenal WAT and BAT was collected from healthy human kidney donors (Svensson 
et al., 2014). Moreover, preadipocytes from interscapular WAT and BAT were isolated 
from C57Bl/6 male mice and immortalized at Joslin Diabetes Center using SV40 virus. 
These immortalized preadipocytes and the commonly used cell line 3T3-L1 are 
genetically manipulated so they can proliferate indefinitely, and are often quick to grow, 
easy to culture, well characterized and theoretically homogeneous. However, because 
immortalized cells are genetically modified, they may not exhibit the exact same 
functions as the normal unmanipulated cells and could sometimes acquire altered 
phenotypes. Hence, immortalized cells might differ more in gene expression patterns 
and biological functions from in vivo cells, as well as from freshly isolated primary cells. 
Another reason for the fresh primary cells being more similar to the in vivo growing 
cells is that they are not expanded through passages, which can cause a selection towards 
a specific cellular subtype and reduce the heterogeneity seen in adipose tissue. In 
addition, passaging cells can allow for occurrence of spontaneous mutations, which may 
in theory alter important cellular functions. However, isolating primary cells is time-
consuming and costly, and heterogeneity of the cell population seeded may cause 
variations between experiments, and the experiments cannot readily be repeated at a 
later time-point with fresh cells from the same subject. Nonetheless, primary adipocytes 
can be frozen, but this often requires some expansion first, which might alter cell 
composition and function. Also, the freezing alone might alter cell characteristics and 
thus their ability to differentiate, discussed further below.   
Human primary, immortalized human, immortalized mouse WAT and BAT, and murine 
3T3-L1 preadipocyte were all differentiated using adipogenic “cocktails” as outlined in 
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the respective papers. There are differences between the in vitro differentiation protocols 
used for mouse and human adipocytes, including the duration of the differentiation 
process. The murine cells reach mature levels after 8 days of differentiation, whereas 
the human cells are subjected to an adipogenic cocktail for around 12 days. In addition, 
the concentrations of substances used in the cocktails differ between the protocols, as 
well as some of the compounds that induce differentiation. The murine preadipocytes 
are induced to differentiate using medium complemented with fetal bovine serum (FBS), 
L-glutamine, insulin, dexamethasone, methyl-isobutyl-xanthinin (IBMX) and 
rosiglitazone (Dankel et al., 2014). The human adipogenic cocktail contains FBS, biotin, 
triiodothyronine (T3), DL-Pantothenate, transferrin, cortisol, insulin, hepes and rosi, the 
latter only for the first 6 days (Veum et al., 2012). Biotin is a coenzyme that regulates 
lipid and amino acid metabolism (Kuri-Harcuch, Wise and Green, 1978), and together 
with Pantothenate and transferrin, it increases lipid accumulation and adipogenesis 
(Wang et al., 2018). T3 is an active form of thyroid hormone, which activates 
phosphatidyl inositol 3-kinase (PI3K), causing increased expression of adipogenic genes 
such as leptin and PPAR-γ (Obregon, 2008; Oliveira et al., 2013). Insulin activates TFs 
that are important in regulating adipogenesis and increases GLUT4-mediated uptake of 
glucose into adipocytes (Laviola et al., 2006), and the synthetic PPAR-γ agonist 
rosiglitazone enhances adipogenesis by enhancing the activation and expression of 
PPAR-γ (Albrektsen et al., 2002). Dexamethasone, a synthetic glucocorticoid, promotes 
expression of, e.g., cAMP Respons Element Binding Protein (CREB) which is a TF 
responsible for expression of adipogenesis inducing genes (Reusch, Colton and Klemm, 
2000), and the phosphodiesterase inhibitor methyl-isobutyl-xanthine (IBMX) also 
exerts its effect by stimulating expression of this TF (Petersen et al., 2008).  
Interestingly, frozen human primary preadipocytes did not differentiate well without 
addition of IBMX to the differentiation cocktail, which is surprising because the fresh 
cells did not need IBMX to induce adipogenesis. On the contrary, we found that addition 
of IBMX hampered differentiation of freshly seeded preadipocytes. Jia et. al have 
previously demonstrated that IBMX supplementation is critical for obtaining 
differentiation of Adipose-Derived Stem Cells (ASCs), however they do not mention 





addition, we surprisingly did not detect appreciable levels of SLC7A10 mRNA in fully 
differentiated adipocytes from ASCs that had been frozen, even when supplementing 
the adipogenic cocktail with IBMX. Together, these lines of evidence suggest that 
passaging or freezing primary preadipocytes introduces alterations in cell characteristics 
and/or might exert a selection pressure towards one specific adipocyte progenitor 
subtype which needs IBMX to differentiate. Because of the many uncertainties with 
using the less characterized frozen cells, we restricted our in vitro human primary cell 
experiments to freshly isolated preadipocytes. The frozen and fresh cells are now being 
characterized by members of our group, since the exact nature of the cell models we are 
working with needs to be further resolved, e.g., by FACS sorting of specific 
subpopulation of progenitor cells. 
It is also important to consider the difference in adipogenic potential of cells from 
different patients. Preadipocytes from some individuals might have a better genetic and 
epigenetic foundation to differentiate compared to others, with possible impact on risk 
of T2D (Claussnitzer et al., 2014). When hASCs from people with both obesity and T2D 
was cultured and differentiated in vivo, they were found to retain their memory of the 
donor due to epigenetic reprogramming, which affected several genes known to regulate 
fat tissue function (Andersen et al., 2019). Therefore, we did not utilize preadipocytes 
from donors having T2D in any of our in vitro studies. Moreover, the individual 
variations in cell composition in the donor adipose tissue might also play an important 
role in how well a pool of preadipocytes differentiate.  Another issue is that highly 
differentiated adipocytes, containing a lot of lipid droplets, are more fragile and can 
detach more easily than less differentiated fat cells. This might, at least in part, be due 
to the changes in cell morphology throughout differentiation, when the cells go from 
being long and fibroblast-like to round and less attached to the surrounding surface. 
Hence, some methodological precautions must be taken to prohibit the mature 
adipocytes from loosening from the cell plate. One solution to this is to coat the plates 
with gelatin or collagen, ensuring that the cultured adipocytes have more than just a 
plastic surface to adhere to, making them attach more strongly to the bottom of the wells. 
Moreover, it is also of great importance to remove and add cell medium slowly, but not 
too slow, because this might cause the cells to dry up. The repeated medium changes 
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throughout adipogenic differentiation poses a greater risk of mechanical stress on the 
cells. To avoid generating differences in stress and number of detached cells between 
different treatment groups that might introduce undue technical variability, it may be 
important, especially in 96-well plates where all the medium is removed at the same 
time by inverting the plate, to vary between which wells are given medium first and last. 
Replicating findings also minimizes the impact of these potential biases on the scientific 
results. Therefore, a major strength of this study is that we have replicated our results 
from multiple metabolic and cellular assays both several times in the same model, but 
also across different human and mouse adipocyte cell models described above. 
Moreover, consistent effects on cellular functions across models and species support 
that the molecules of interest are in evolutionarily conserved and hence involved in 
important molecular processes.  
 
3.4 Treatment of cultured cells using pharmacological and natural compounds, 
and transient overexpression or knockdown 
Modulation of SLC7A10 for the functional assays in paper 1 and 3 was mainly 
performed by using the pharmacological inhibitor entitled BMS (Brown et al., 2014), 
but we have also confirmed multiple key results using the inhibitor LU (Sason et al., 
2016) and by observing opposite results when overexpressing adipocytic SLC7A10. 
Inhibitors may however cause unspecific phenotypic effects. We therefore examined the 
effect of the two SLC7A10 inhibitors on cell viability by using the neutral red 
cytotoxicity assay, following the manufacturer’s protocol (Abcam, ab234039). We 
found no differences in cell viability compared to cells treated with normal medium with 







Figure 5. Slc7a10 inhibitors lack cytotoxic effects: 3T3-L1 cells were treated with either DMSO (vehicle), BMS 
(SLC7A10 inhibitor 1) (100 µM), LU (SLC7A10 inhibitor 2) (100 µM), or 3-HIB (0.1 or 10 mM) for 72 hours 
during different stages of differentiation to assess for effects on cell viability. Doxorubicin (5mM) was used as a 
positive control for known cytotoxic effects. Treatment lasted for 72 hours from D-2 to D0 and D2 to D5 of 
differentiation, and on the day of the assay (day 1 for early differentiation and day 6 for late differentiation), cells 
were washed and incubated in freshly diluted neutral red dye solution for 2 hours. Following solubilization, cell 
viability was measured as a function of neutral red dye taken up through active transport by live cells, as measured 
spectrophotometrically at 540nm. Data are presented as mean ± SD (n=8-10).  
 
Also, both the inhibitors’ specificity and mechanisms of action have been thoroughly 
examined previously (Brown et al., 2014; Sason et al., 2016; Torrecillas et al., 2019; 
Mikou et al., 2020). BMS is suggested to have two mechanisms of action. Firstly, it 
works by competitive inhibition, whereby it occupies the orthosteric (active) site of 
SLC7A10, where the transported amino acids usually are bound before they are 
transferred through the plasma membrane inside the transporter. Secondly, BMS inhibits 
the transport non-competitively, by also binding an allosteric site, blocking the 
movement of transmembrane helixes required for transport of amino acids (Torrecillas 
et al., 2019). LU is suggested to work in a similar manner, also blocking the rocking of 
the moieties that inhibit the transport process (Mikou et al., 2020). However, it is 
important to note that these studies are based on computational techniques, specifically 
homology modelling, since no X-ray crystallographic structure of SLC7A10 has yet 
been resolved. The structures of membrane proteins are generally difficult to elucidate, 
because they are often hard to express in large enough amounts, and to solubilize and 
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thereafter crystallize (Doerr, 2009). In addition, the studies that have examined 
mechanisms of SLC7A10 inhibitors have looked mostly at the influx and efflux of D-
serine, and thus focused less on the flux of the other SLC7A10-transported amino acids. 
Furthermore, the authors do not mention whether the diffusion mode is also completely 
blocked, since SLC7A10 is able to work through facilitative diffusion, in addition to 
exchange mode (Fukasawa et al., 2000). However, this seems very likely since the 
transporter is stuck in the open-outward facing confirmation when inhibited by both 
transporters, which indicates that the transporter is closed on the cytosolic side 
(Torrecillas et al., 2019; Mikou et al., 2020), blocking diffusion of amino acids through 
the transporter channel. 
In addition to treating adipocytes with inhibitors, we attempted to knock down Slc7a10 
using several small interfering RNA (siRNA) constructs, transfection reagents and 
varying the experimental settings in both mouse and human cells. However, we did not 
manage to reduce the Slc7a10 mRNA expression and lacking functional assays with KD 
is a limitation of our in vitro study. On the other hand, we successfully overexpressed 
Slc7a10 in 3T3-L1 adipocytes, causing opposite effects on several functional assays 
compared to inhibition. 
For Paper 2, the main modulation of BCAA metabolism is performed by either treating 
cells with the valine breakdown product 3-HIB or knocking down the valine 
catabolizing enzyme HIBCH. Supra-physiological concentrations (10 mM) of 3-HIB 
were initially used in our experiments and had no effects on cell viability (Figure 5). In 
addition, we examined the cellular effects of supplementing cell cultures with multiple 
doses of 3-HIB, which also did not affect cell viability (Figure 5), and we observed 
similar results between concentrations in several of our function assays. Furthermore, 
the Hibch KD efficiency in murine WAT and BAT, and 3T3-L1 cells was high, and 







3.5 RNA sequencing and gene ontology analyses (Paper 1 and 3) 
Paper 1 contains an analysis examining genes that are co- or anti-expressed with 
SLC7A10 in adipocytes isolated from patients, RNA sequencing results from VAT of 
Slc7a10b WT and loss-of-function zebrafish, and from cultured Dimethyl sulfoxide 
(DMSO) and BMS-treated human primary adipocytes. Genes found to be highly co- or 
anti-expressed, or significantly different between treatment and control were subjected 
to ontology analyses, mainly using the freely available online tools Panther (Thomas et 
al., 2003) and GOrilla (Eden et al., 2007, 2009).  
Gene ontology (GO) analyses are often performed to screen for patterns of biological 
processes or pathways strongly affected by a specific modulation. For the Zebrafish 
RNA-seq, we had to pool the collected tissues from the three fish in each tank together 
to obtain enough RNA for the analysis. This resulted in less samples, and hence a lower 
statistical power. Due to the vast number of genes tested in these types of analyses, it is 
important to correct for multiple testing when calculating p-values. After both reducing 
the number of samples and correcting for multiple testing, we obtained a more reliable 
list of genes that significantly varied in expression between WTs and mutants. When 
subjecting the up- and down-regulated genes to GO databases to screen for possible 
biological processes that were affected, there were few significant categories. However, 
since we had pooled RNA from 3 different fish for each sample we analyzed for RNA 
seq, the genes found to be significantly differing between the WT and mutants actually 
has a three times higher n than the number of tanks used. Therefore, the genes identified 
by analysis of the RNA sequencing results can be considered strong candidates for 
mediating the effects of impaired SLC7A10 function. This is however not taken into 
consideration in the statistical analysis, since the analysis only knows the total n of the 
samples (each tank), and we got a shorter list of significant genes differing between the 
WT and the mutant. We therefore performed an alternative analysis using GOrilla, 
which could take advantage of the large number of genes that showed a large fold 
difference between the WT and mutant fish. All genes were organized into a single 
ranked list based on fold change and subjected to a GO analysis in an made for ranked 
46 
 
lists in Gorilla. This alternative analysis is an advantage of Gorilla when samples show 
more variation in gene expression.  
For the RNA-seq from the DMSO and BMS-treated human primary adipocytes, we had 
more samples and the effect of BMS on global gene expression was strong, which 
resulted in a large number of significant up and down-regulated genes compared to 
DMSO. Here we used a multiple testing-corrected p-value < 0.05 and looked at both 
significantly affected cellular pathways and biological processes. When deciding these 
cut offs, there are no definite rules to follow. However, these analyses are typically 
hypothesis-generating that need further validation with functional experiments. 
Rerunning GO analyses with different p-value cut-offs and tools can help to highlight 
the functional categories that are most robustly associated with the 
treatment/manipulation of interest, giving a greater likelihood that effects will be 
observed in corresponding functional assays. Also, applying different GO strategies to 
analyze transcriptome data, including gene set enrichment analysis (GSEA), can provide 
additional insight and confidence in functional predictions.  
Generally when interpreting gene expression analyses, it is important to consider that 
even though the measured alterations in gene expression can indicate which pathways 
and mechanisms are affected by a specific treatment, they might not give a 
straightforward picture of the cellular condition. Firstly, even though a gene is highly 
transcribed into mRNA, it is not necessarily further translated into protein. Several 
down-stream regulatory mechanisms can either make the mRNA dormant or send it for 
degradation. Also, the protein sequence might not undergo the required post-
translational modifications to be functional or be activated (e.g., by being 
phosphorylated by up-stream proteins in a cellular signaling cascades). In addition, the 
directionality of differentially expressed genes between BMS and DMSO might also be 
difficult to interpret. Up- or down-regulated genes might reflect an attempt to 
compensate for the reduced function of SLC7A10. This can be exemplified by the 
increased mRNA expression of Slc7a10b observed in adipose tissue of the Slc7a10b 
loss-of-function zebrafish, and in the BMS treated cells showing higher SLC7A10 





of the observed functional ontologies, transcriptome studies are useful for obtaining an 
overview of affected pathways and processes. Overlap of the same overrepresented 
biological processes in different data sets and organisms, where the same factor has been 
modulated, can further increase confidence in the relevant processes to investigate 
further. Therefore, the overlapping genes and GO results from the Zebrafish and BMS 
RNA-seqs are likely to be more biologically and functionally relevant, strengthening the 
individual results. To further confirm biological relevance, we have used Western blot 
to look into protein expression to confirm gene expression results and performed 
functional assays to more specifically investigate the metabolic pathways and biological 
processes affected.  
 
3.6 Metabolomics, functional assays, and normalization  
Several methods and assays are applied to the various cell models utilized in the present 
thesis. Among others, we have performed metabolomics measuring amino acids and 
metabolites in medium samples from cultured adipocytes by GC-MS at Bevital AS, and 
conducted multiple functional assays, measuring radiolabeled amino acid and glucose 
uptake, mitochondrial respiration, lipid staining by Oil Red O (ORO), ROS generation, 
total GSH concentrations, FA uptake, and total cholesterol and glycerol levels. 
When collecting the medium from cells in culture for metabolomics analyses, there are 
several pitfalls to be aware of. Firstly, it is important to collect the medium at the same 
timepoint each day since the flux is calculated per hour and the measured amino acid 
and metabolite concentration will be inaccurate if the timing varies too much. We kept 
all collection within less than one hour away from 24 or 48 hours. Secondly, the medium 
should be collected in the same way every time, with the same number of resuspensions 
and tilting of the cell culture plate. This ensures that the amino acid concentrations 
measured at the different timepoints can be comparable. Lastly, all the medium should 
be removed before the cells are subjected to the fresh medium, since this might affect 
the total cellular uptake or synthesis of amino acids, or the leftover extracellular amino 
acids might add to the concentration of measured amino acid in the next measurement, 
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rendering the data imprecise. This is also important when considering that 
unconditioned medium is used as a reference when calculating the total flux. Another 
aspect to consider is the amino acids produced by the cells, which is a dynamic process 
dependent on the needs of the cells. Therefore, the results calculated reflect the net 
balance of fluxes in and out of the cell, i.e., the amount of amino acids and metabolites 
taken up from the medium into the cells (when calculating uptake) and released to the 
extracellular fluid or not taken up (when calculating influx). Hence, unless also 
collecting the cells, nothing is known about the intracellular amino acid and metabolite 
status in these experiments, and about the total contribution of cellularly synthesized 
amino acids to the result, except for the essential amino acids which cannot be produced 
in mammalian cells. In one of the metabolomics experiments in Paper 2 we also 
subjected intracellular cell lysates to metabolomics analysis. This was however not 
feasible in experiments where cells were treated with compounds, due to the large 
number of cells needed to have enough lysate for the measurement, requiring copious 
amounts of compound. For the intracellular experiments, cells from 6 confluent 15 cm 
dishes were typically combined for any timepoint of interest. 
In general, functional assays are used to examine, in a controlled and specific manner, 
effects of treatments on various cellular pathways and biological processes compared to 
control, such as mitochondrial respiration, cell stress and fat storage (Simpson, 2006). 
In the present work we utilize the seahorse mitochondrial stress test assay to measure 
respiration in living cells. Briefly, this method is based on measuring oxygen 
consumption rate (OCR), while modulating the function of the molecules in the electron 
transport chain. For this assay, it is important that the pH of the Seahorse medium is 
adjusted to 7.4 at 37°C. If this is not done correctly, it might affect the oxygen 
measurements performed by the Seahorse machine, and different experiments cannot be 
directly compared. When measuring oxidative stress in adipocytes, we use a commonly 
used ROS probe, which emits fluorescence when exposed to oxidation. When 
conducting the ROS assay, the probe must be protected from light, to avoid excitation. 
In addition, when measuring difference in ROS generation between treatments, the 
compounds examined should be added to the cells in close vicinity to the 





(representing the baseline ROS before treatment). Since the FA uptake assay is also 
fluorescence based, and uses a light sensitive FA substrate that emits fluorescence when 
taken up into the cell, many of the same considerations as for the ROS assay are 
important for this assay as well. Furthermore, both amino acid and glucose uptake 
measurements are performed with molecules labeled by carbon-14 or hydrogen-3. For 
all radioactive assays, it is important to keep as much distance to the radioactive source 
as possible, and to have detailed protocols in place describing which protective 
equipment to wear and how the experiment can be conducted in a safe and effective 
manner. It is also important to keep the number of radioactive experiments to a 
minimum, while having enough replicates to obtain the required power, and to have safe 
disposal routines in place before starting.  
To control that the measured effects are due to the specific treatment and not artifacts of 
for example different cell number due to variation in attachment, growth or the amount 
of mechanical stress applied between wells, all results from functional assays should be 
normalized to a direct or surrogate measure of viable cells. This is not always 
straightforward and finding the best normalization method requires planning, as well as 
knowledge of both the methodology the assay utilizes and the cellular pathways 
affected. Firstly, in assays where the cells are lysed before readout, results cannot be 
normalized to the cell count in each well by Hoechst staining. Therefore, only ROS, 
Seahorse and FA uptake assay, which are all performed in live cells, can be normalized 
to cell number in the plates after the assay is finished. This is, in my opinion, the most 
robust way of normalizing results from functional assays. Nevertheless, there is also one 
issue with this normalization methods, namely that cells might loosen during the assay. 
The ROS, Seahorse and FA uptake assays are all run for several hours, but Hoechst 
staining can only normalize the measured result to the number of cells attached in each 
well at the end of the experiment. However, since these assays are all run in machines 
with a persistent temperature of 37 °C, to prevent cells from loosening, and all wells are 
treated the same way, this method of normalization should give reliable results. In 
addition, one should ensure accurate seeding of cells into each well and start treatment 
only after cells have stopped proliferating and started to develop into adipocytes. This 
will keep the cell number in each well as similar as possible and is thus important when 
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utilizing all normalization methods. Secondly, assays where cells are lysed before 
readout can be normalized to for example the protein or deoxyribonucleic acid (DNA) 
concentration measured in each well, as a surrogate measure of cell number. Assays that 
are normalized to protein concentration include glucose uptake, while total GSH levels 
are normalized to DNA concentration. However, when treating cells throughout 
differentiation, protein and DNA concentration in each cell could be affected. 
Nevertheless, treating terminally differentiated adipocytes for a short time (minutes to 
24 hours) with various compounds should normally not affect these measures markedly. 
In addition, the amount of DNA is not affected in the cells that have started to 
differentiate, since they no longer undergo mitosis. DNA is also more robust compared 
to protein and can resist degradation during prolonged exposure to higher temperatures 
and other suboptimal conditions. Therefore, normalization to DNA is in my opinion the 
best way to normalize results from cells that are no longer attached to the surface of the 
wells. Ideally, we should have utilized DNA concentration to normalize results from all 
assays using lysed cells.  
In conclusion, no normalization method is perfect, but if the effect of the compound is 
strong enough, the appropriate methodological measures and considerations are taken, 
and the results are replicated several times, the end results of the functional assay should 
reflect the cellular in vitro situation in response to a treatment of interest.   
 
3.7 Statistics and sample variation  
The specific statistical methods used in this thesis are described in detail in each 
individual paper. Briefly, we used two-tailed unpaired Student T-test when comparing 
two different groups, one-way ANOVA with Dunnett’s or Sidak’s correction for 
multiple comparisons when comparing more than two groups and DESeq2 for 
differential expression analysis of RNA-seq data. In Paper 1 and 3, data are presented 
as mean ± SD (standard deviation) or as geometric mean ± 95% confidence intervals 
(only Seahorse data).  The latter was utilized when describing Seahorse data, due to a 





2, data are visualized by mean ± SEM (standard error of the mean) or mean ± 95% 
confidence intervals (HUSK data). For data with less than 2 replicates (n<2), no measure 
of dispersion is shown, and significance is always indicated by *P < 0.05, **P < 0.01, 
***P < 0.001.  
When performing experiments in human primary preadipocytes, there might be natural 
variation between the samples from different people in how the cells behave. This might, 
as mentioned previously, be due to genetics, epigenetics and the physiological state of 
the person and tissue the cells were isolated from. These cells, purified from liposuction 
aspirate from the abdomen, are not genotyped, and we only have access to clinical data 
limited to sex, BMI, relevant diseases history, and whether they previously have had 
bariatric surgery. To exclude sex-specific differences, we have mainly utilized primary 
preadipocytes from women (except from one man). However, it is important to take into 
account that these preadipocytes are all treated similarly when and after they are 
isolated, and a strength of the SLC7A10 inhibitor treatment is that it consistently leads 
to a similar response in cells from all of the different subjects. As discussed previously, 
cell cultures are more similar genetically, which makes different experiments more 
comparable. Correlation analyses of cohort data were adjusted for BMI, sex, and age. 
For the zebrafish used in the overfeeding study in Paper 1, they were all siblings, and 
therefore retain similar genetics. When working with biological data, it can therefore 
often be difficult to know whether a deviating data point is an outlier due to an actual 
error in the analysis or a biologically relevant finding caused by interindividual 
differences. Conducting standardized outlier tests helps to present the data in an 
unbiased and robust way. In the present thesis, outliers are consistently removed using 
a Whisker Tukey test before visualizing the data. 
Overall, utilizing clinical data from several human cohorts, and making consistent 
observations in both in vitro cultured primary human adipocyte and mouse cell models, 








4. Summary of results 
4.1 Paper 1: Role of the neutral amino acid transporter SLC7A10 in adipocyte 
lipid storage, obesity and insulin resistance 
In this study, we sought to investigate molecular mechanisms in adipocytes that affect 
IR and T2D risk. In multiple human cohorts, including the Western Norway Obesity 
Biobank (WNOB), SAT expression of the neutral amino acid transporter SLC7A10 was 
consistently negatively associated with plasma TAG levels, IR, visceral adiposity and 
adipocyte size. To examine the isolated effect of SLC7A10 impairment in vivo, we 
overfed Slc7a10b loss-of-function and WT zebrafish for 8 weeks, and found that the 
transgenic fish gained more weight and developed larger adipocytes compared to their 
WT counterparts.  
To investigate how impaired SLC7A10 function directly affects adipocyte metabolism, 
we treated cultured 3T3-L1 mouse and primary human adipocytes using two different 
SLC7A10 inhibitors. We observed that SLC7A10 protein and mRNA expression 
increased during adipogenesis, and when inhibiting SLC7A10 throughout 
differentiation, we found a potent increase in lipid accumulation in both the murine and 
the human adipocytes compared controls. By performing RNA-seq on differentiating 
human adipocytes treated with SLC7A10 inhibitor for 24 hours, we observed an 
overrepresentation of significantly affected genes related to multiple metabolic 
processes, such as ATP synthesis, TCA cycle, cholesterol biosynthesis and glycolysis. 
Furthermore, we found that SLC7A10 impairment reduced mitochondrial respiratory 
capacity in the cultured adipocytes. Conversely, overexpression of Slc7a10 significantly 
increased mitochondrial respiratory capacity in murine 3T3-L1 adipocytes.  
Overlapping of RNA-sequencing data from VAT of the loss-of-function zebrafish with 
the inhibitor-treated human primary adipocytes revealed consistent changes in gene 
expression and in affected biological processes, such as triglyceride metabolic, 
oxidation reduction and alpha-amino acid catabolic processes. Since SLC7A10 is 
known to transport small neutral amino acids in the brain, we investigated how 
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inhibition of the carrier affected the flux of these amino acids in adipocytes. Impairment 
showed no significant effect on cysteine, alanine, threonine and glycine flux, but a 
marked reduction in serine uptake into mature adipocytes. Because serine is a known 
precursor for the body’s primary antioxidant, GSH, the reduced uptake prompted us to 
assess total GSH levels. Adipocyte SLC7A10 inhibition decreased cellular levels of 
GSH, and consequently increased generation of ROS, while overexpression of Slc7a10 
reduced ROS generation. Treatment with ROS scavenger decreased the fat accumulation 
in SLC7A10 inhibitor-treated adipocytes to levels similar to the control without 
scavenger present, but did not significantly counteract  the lipid-storing effect of insulin, 
suggesting ROS-dependent lipid accumulation upon reduced SLC7A10 activity but not 
upon increased insulin stimulation. In addition, SLC7A10 impairment reduced insulin-
stimulated glucose uptake, further indicating that increased glucose uptake did not 
promote the observed increase in fat storage and that SLC7A10 directly affects 
adipocyte insulin sensitivity. 
In conclusion, we here identified SLC7A10 as a novel modulator of white adipocyte 
metabolism, inversely associated with obesity, IR and increased risk of common 






4.2 Paper 2: 3-Hydroxyisobutyrate, a strong marker of insulin resistance in type 2 
diabetes and obesity that modulates white and brown adipocyte metabolism 
In this study, we examined how impaired adipocyte catabolism of BCAAs and 
stimulation with extracellular valine catabolite 3-HIB, affect metabolic mechanisms in 
white and brown adipocytes, and the possible role of 3-HIB in the development of IR 
and T2D. We analyzed several large cohorts including the Hordaland Health Studies 
(HUSK) and WNOB, and found a strong elevation of circulating 3-HIB in insulin 
resistance and a gradual increase from normoglycemia to hyperglycemia and established 
T2D. Moreover, we found a significant positive correlation between plasma 3-HIB 
concentration and metabolic risk traits including BMI, HOMA2-IR, glucose and TAG 
levels, and observed a reduction in serum 3-HIB levels in two different cohorts one year 
after bariatric surgery. Interestingly, one-week post-surgery we found an increase in 
circulating 3-HIB levels, which might reflect the acute metabolic adaptations to 
maintain whole-body energy homeostasis in a condition of reduced nutrient intake.  
To gain new insight into BCAA catabolism and 3-HIB in adipocyte metabolism, we first 
measured amino acid and metabolite flux throughout differentiation of cultured human 
primary and 3T3-L1 murine adipocytes. We found increasing BCAA uptake and 3-HIB 
release during adipogenesis, with a concomitant increased expression of BCAA 
catabolic enzymes. The latter was also replicated in immortalized mouse WAT and BAT 
cells. Furthermore, knockdown of HIBCH, an enzyme responsible for catabolism of the 
valine metabolite 3-hydroxy-isobutyryl-CoA to 3-HIB, decreased lipid accumulation in 
and 3-HIB release from all the mouse cell models examined.  
Lastly, we observed that 24-hour treatment with 3-HIB increased insulin-stimulated 
glucose uptake in both WAT and BAT cells, while shorter-term (3-hour) treatment 
reduced insulin-dependent glucose uptake. On the other hand, short-term 3-HIB addition 
increased FA uptake in both adipocyte subtypes, but decreased mitochondrial 
respiration and ROS generation in WAT, while increasing both of these cellular 
processes in BAT.  
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In conclusion, we identified 3-HIB as a novel adipocyte-released signaling metabolite, 
strongly linked to metabolic syndrome, that regulates nutrient uptake and important 






4.3 Paper 3: Impaired adipocyte SLC7A10 function promotes lipid storage in 
association with altered BCAA metabolism and TCA cycle activity in insulin 
resistance 
Having found reduced insulin-dependent glucose uptake with a concomitant increase in 
lipid accumulation in SLC7A10-inhibited adipocytes compared to control, we here 
hypothesized that extracellular amino acids served as substrates for the increased TAG 
synthesis and storage.  
We subjected RNA-sequencing data from human primary adipocytes treated with 
SLC7A10 inhibitor to a gene set enrichment analysis (GSEA), after manually compiling 
comprehensive gene lists for metabolic pathways involved in lipid storage as well as for 
genes involved in metabolism of each of the 20 primary amino acids. The GSEA 
revealed that multiple processes related to lipid metabolism were significantly altered 
compared to control, such as glycerophospholipid metabolism, TCA cycle, cholesterol 
biosynthesis, FA transport and TAG metabolism. When treating mature 3T3-L1 
adipocytes with SLC7A10 inhibitor for 24 hours, we observed no effect on FA uptake 
or cholesterol content, and a surprising reduction in glycerol content. However, in 
response to SLC7A10 impairment from day 2 to 8 of differentiation, all these processes 
increased significantly compared to control. Moreover, 24-hour SLC7A10 impairment 
during differentiation of human adipocytes markedly increased expression of genes 
involved in glyceroneogenesis, the key process for TAG synthesis in adipocytes, where 
glycerol is synthesized from the TCA cycle intermediate oxaloacetate.  
The GSEA for amino acid metabolism revealed a significant enrichment for BCAA 
metabolism, with upregulation of several key enzymes in this biological process. A 
significant upregulation was also observed for several genes encoding enzymes in the 
phenylalanine and tyrosine, aspartate and asparagine, and lysine metabolic pathways. 
To explore if these changes in gene expression reflected altered amino acid consumption 
and changes in TCA-related metabolites, we performed GC-MS analysis on conditioned 
medium from human primary adipocytes treated with SLC7A10 inhibitor throughout 
adipogenesis. We observed increased consumption of all the BCAAs, no change in the 
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net flux of methyl malonic acid (MMA), and a potent increased efflux of valine 
catabolite 3-HIB compared to controls, the latter consistent with SLC7A10-mediated 
increase in protein expression of the 3-HIB generating enzyme HIBCH.  
Furthermore, the comprehensive GC-MS analysis confirmed reduced serine uptake, but 
also indicated a decrease in alanine efflux and increased consumption of aspartate. 
Glutamate uptake was significantly increased in mature adipocytes, in line with 
decreased expression of the glutamate generating enzyme GLS, and increased uptake of 
the glutamate catabolic product and TCA cycle intermediate α-ketoglutarate.  
Finally, we examined baseline data from the human cohort MyoGlu consisting of 
lean/overweight people with normoglycemia (NG) and dysglycemia (DG), to assess the 
in vivo relationship between adipose SLC7A10 and amino acid and metabolite plasma 
levels. In this cohort, SLC7A10 mRNA expression in subcutaneous adipose tissue was 
inversely associated with BMI, circulating TAG levels and total fat mass and fat mass 
in several different body compartments. In addition, subcutaneous SLC7A10 expression 
correlated positively with MMA, and negatively with plasma levels of all the BCAAs 
and 3-HIB. When dividing the study participants into NG and DG, we observed 
significantly reduced subcutaneous SLC7A10 expression in DG compared to NG, and 
the opposite effect on circulating 3-HIB levels.  
Overall, our study indicates that increased uptake and catabolism of BCAAs, aspartate 
and glutamate contribute to fueling FA and glycerol synthesis upon impaired SLC7A10 
function, in the context of decreased insulin-stimulated glucose uptake. The high 3-HIB 
plasma levels, associated with IR, may partly reflect decreased adipocyte SLC7A10 







5. General discussion  
5.1 SLC7A10, 3-HIB and catabolism of specific amino acids in adipocyte biology 
To look into the mechanisms by which adipocytic SLC7A10 and amino acid metabolism 
affect adipocyte biology and dysfunction, we performed transcriptome analyses and 
consequent functional assays and found consistent effects on multiple cellular processes, 
such as amino acid, glucose and FA uptake, mitochondrial respiration, ROS generation 
and fat storage (Figure 6). 
 
Figure 6. Overall findings of the functional studies in Paper 1, 2 and 3. The relationship between the main 
functional findings of Paper 1 (green background), Paper 2 (pink background) and Paper 3 (yellow background) 
are illustrated here, as well as the key results from each paper. ROS; reactive oxygen species, Mito. Respiration; 
mitochondrial respiration, FA uptake; fatty acid uptake.  
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5.1.1 Altered amino acid flux and catabolism regulates adipocyte metabolic 
processes 
One of the main findings of this thesis is the reduced serine uptake when SLC7A10 is 
inhibited in adipocytes, and the increased influx and catabolism of other amino acid, in 
particular the BCAAs, with associated effects on several metabolic processes (Figure 
6). The decreased serine influx we observe is consistent with previous findings of 
SLC7A10’s function in the brain, where inhibition impairs flux of both L- and D-serine 
in neurons (Matsuo et al., 2004; Rutter et al., 2007; Sason et al., 2016). In several cell 
types, serine catabolism has been found to be required for many critical cellular 
processes, including biogenesis of mitochondria and translation of proteins (Minton et 
al., 2018), fueling lipid metabolism, oxidative phosphorylation and purine synthesis, 
and maintaining redox balance (Yang and Vousden, 2016; Newman and Maddocks, 
2017a). These roles of serine are in line with the affected processes we observe in 
adipocytes in vitro when SLC7A10 function is impaired, however, not necessarily in the 
same direction as observed with serine deprivation in some other cell types.  
 
Interestingly, several of the studies performed on the sodium-independent SLC7A10’s 
carrier function in brain cells also find effects on glycine transport (Ehmsen et al., 2016; 
Mesuret et al., 2018). In adipocytes, we observe a small reduction in glycine uptake 
when performing radioactivity experiments using sodium-free assay buffer with and 
without SLC7A10 inhibitor present. This decrease in glycine influx supports that 
adipocytic SLC7A10 is capable of transporting glycine in fat cells, but our data suggest 
that this occurs only in experiments without sodium available (Verrey et al., 2004). In 
more “physiologically relevant” conditions (here normal differentiation medium), we 
find no differences in net glycine flux when SLC7A10 function is impaired compared 
to vehicle. However, in contrast to the intracellular measurement of radiolabeled 
glycine, from these measurements in culture medium we cannot know whether both 
influx and efflux of glycine were altered to a similar extent, which would result in no 
change in the net uptake even though there might have been intracellular changes in 






Upon SLC7A10 inhibition during adipogenesis, the uptake of the negatively charged 
amino acids glutamate and aspartate was increased. Glutamate can be converted into the 
TCA intermediate α-KG, while aspartate is catabolized to oxaloacetate (Martínez-Reyes 
and Chandel, 2020). Together with the increase in uptake and catabolism of the BCAAs, 
which can be directed towards the TCA cycle via generation of propionyl-CoA or acetyl-
CoA (Ye et al., 2020), the increased influx of these amino acids may fuel 
glyceroneogenesis and de novo FA synthesis (Reshef et al., 2003). Together, the 
increase of these processes may, at least in part, promote the increased fat storage seen 
when SLC7A10 is perturbed. This mechanism helps to explain how the adipocytes could 
increase lipid accumulation despite the decreased insulin-stimulated glucose uptake 
upon SLC7A10 inhibition. Our data and previous studies in 3T3-L1 adipocytes 
particularly implicate increased uptake of BCAAs in lipid storage during adipogenesis 
(Green et al., 2015; Nilsen et al., 2020), where BCAAs may replace around 30% of the 
glucose and glutamine that is otherwise used to fuel proliferating cells, in order to 
provide substrates for lipogenesis (Green et al., 2015). Another interesting finding in 
this thesis is the increase in cellular cholesterol levels and expression of cholesterol 
synthesis genes when adipocyte SLC7A10 is impaired. A previous study links 
cholesterol synthesis in late adipogenesis to increased catabolism of leucine (Halama et 
al., 2016), which is consistent with our findings. Taken together, the effects of SLC7A10 
inhibition on adipocyte metabolic processes is most likely caused by both the decreased 
serine influx, and also involves increased uptake and consumption of other lipogenic 
amino acids.   
 
5.1.2 Altered ROS generation and lipid and energy metabolism 
Strengthening the link between adipocytic SLC7A10 and fat storage, is our novel 
finding showing increased release of 3-HIB when SLC7A10 is impaired. We found that 
higher 3-HIB release follows the pattern of increased adipocyte differentiation, fat 
storage and mRNA expression of HIBCH which removes the CoA moiety of 3-HIB-
CoA, allowing 3-HIB to leave the cell. When we knocked down Hibch in mouse 
adipocytes, we found a decrease in 3-HIB levels in the media, and a 35-40% decrease 
in lipid accumulation. This indicates that valine provides a major source of the carbons 
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that are used to fuel fat storage in adipocytes and/or that 3-HIB release is important to 
promote lipid accumulation. Consistently, studies have found that adipocytes switch 
from using glutamine and glucose as main fuel for TAG synthesis during differentiation 
to utilizing BCAAs (Crown, Marze and Antoniewicz, 2015; Green et al., 2015). 
Conceivably, when 3-HIB exits the cell after Hibch removes the CoA moiety, there may 
be less carbon left from the degraded valine to enter the TCA cycle. On the other hand, 
this provides a free CoA (Taniguchi et al., 1996) that can be used in other metabolic 
processes, for example to further catabolize leucine and isoleucine to propynyl-CoA or 
acetyl-CoA. Thus, future studies should investigate the effect of Hibch KD on the uptake 
of leucine and isoleucine, and possibly also other amino acids, and assess whether these 
may fuel the increase in fat storage associated with 3-HIB release. When impairing 
SLC7A10 we see increased 3-HIB release and HIBCH expression, which is consistent 
with the Hibch KD data. Moreover, we show that there is a somewhat higher relative 
net increase in uptake of leucine and isoleucine when SLC7A10 is inhibited compared 
to valine, while the levels of valine taken up by the cells per hour appear to be higher 
than leucine and isoleucine both with and without impairment of SLC7A10. Other 
studies have found that valine and isoleucine catabolism in adipocytes contribute to 
100% of lipogenic propionyl-CoA (Crown, Marze and Antoniewicz, 2015), while valine 
and isoleucine are responsible for 25-30% of the lipogenic acetyl-CoA (Crown, Marze 
and Antoniewicz, 2015; Green et al., 2015). Thus, the extra leucine and isoleucine 
uptake we observe may, independent of valine, contribute to fuel the excess fat storage 
or, since the valine influx is already high, the amount of valine that is not released as 3-
HIB might be high enough to contribute to the increased lipid accumulation. This should 
however be further explored by future studies, tracing the metabolic route of the carbons 
from the three BCAAs taken up when SLC7A10 is impaired compared to controls. Of 
note, a recent in vivo study that administered radiolabeled BCAAs to mice showed that 
around 20% of 3-HIB in plasma was radiolabeled already within 3 minutes, indicating 
extremely fast turnover in the valine degradation pathway (Neinast et al., 2019). A 






The link between adipocyte 3-HIB release and fat storage, seen in both in Paper 2 and 
3, further strengthens the hypothesis that 3-HIB might function as an autocrine, 
paracrine and/or endocrine signaling molecule, reflecting a state of increased fat storage 
and/or nutrient availability in adipocytes. Previous studies have indicated that 3-HIB 
can increase FA uptake in skeletal muscles and thereby promote IR (Jang et al., 2016), 
while adipose-derived microvascular endothelial cells did not respond to 3-HIB 
treatment (Mardinoglu et al., 2018). In this thesis, we observe a novel 3-HIB-mediated 
FA uptake in both white and brown adipocytes, which might contribute to storing excess 
FAs as lipids in white adipocytes and to catabolizing them via mitochondrial respiration 
and thermogenesis in brown fat cells (Lee, Mottillo and Granneman, 2014). 
Surprisingly, we saw no clear effect on lipid accumulation by 3-HIB treatment in neither 
of the adipocyte subtypes (data not shown). The reasons for this is not clear, but it might 
be due to insufficient FA concentrations in the cell medium when treating with 3-HIB 
throughout adipogenesis, which might differ from the in vivo situation when 
extracellular 3-HIB levels are high. Both the FA uptake assay and the glucose uptake 
assay measure uptake after deprivation of FAs and glucose, respectively. Based on our 
studies we also could not assess how 3-HIB might contribute to increased lipid storage 
by affecting the TAG-FA cycle between adipocytes and other organs (e.g., the liver) 
(Reshef et al., 2003), which would require in vivo studies. Of note, our data show that 
SLC7A10 inhibition, associated with increased 3-HIB release, can increase adipocyte 
glyceroneogenesis which is an important regulator of the TAG-FA cycle (Reshef et al., 
2003).  
  
3-HIB treatment in white adipocytes caused decreased ROS and mitochondrial 
respiration, while the opposite was seen in brown fat cells (Figure X.1). This might be 
due to the large difference in the amount of expressed BCAA catabolic genes that we 
observe between the adipocyte subtypes, where brown adipocytes have the highest 
expression (Nilsen et al., 2020), as well as the different basic functions of brown and 
white adipocytes. In addition, recent reports show that the BCAA catabolizing enzyme 
complex branched-chain 2-oxoacid dehydrogenase (BCKDH), localized in 
mitochondria, can produce O- and H2O2 (oxygen species) at higher rates than complex 
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I in the respiratory chain (Ribas, García-Ruiz and Fernández-Checa, 2014). We observe 
a 9-fold higher expression of Bckdha and 3-fold higher expression of Bckdhb in 
differentiated brown compared to white adipocytes, which might explain the increase in 
ROS seen in brown but not white adipocytes. Conceivably, the increased BCAA uptake 
and BCKDHB expression we observe when SLC7A10 function is impaired might 
therefore also have contributed to elevated levels of ROS.  
Furthermore, the observation that 3-HIB treatment affects ROS and mitochondrial 
respiration is consistent with increased levels of ROS upon higher activity of 
mitochondrial oxidative phosphorylation (respiratory chain) (Rosen et al., 2014; 
Liemburg-Apers et al., 2015). Importantly, a recent study found that adipocyte 
respiration does not increase mitochondrial ROS unless glucose is available, and that 
adipocyte respiration is mainly fueled from other sources than glucose (Krycer et al., 
2020). It is also important to take into account that there are several other known sources 
of cellular ROS production (Engin, 2017) in addition to mitochondrial ROS, such as 
generation by NADPH (Nicotinamide adenine dinucleotide phosphate) oxidases, 
glyceraldehyde auto-oxidation and as by-products from several other cellular pathways 
(Manna and Jain, 2015; Hauck et al., 2019). In SLC7A10-inhibited adipocytes, we 
observe an increased ROS generation (after 15-45 minutes with inhibition) and 
subsequent reduced mitochondrial respiration (24 hours inhibition). Conversely, we find 
that Slc7a10 overexpression in 3T3-L1 adipocytes decreases ROS levels and increases 
mitochondrial respiratory capacity. These data are consistent with a report showing that 
ROS generation decreases respiration in white adipocytes (Wang et al., 2010). Other 
previous studies have reported that controlled ROS production in adipocytes contributes 
to intracellular signaling, and that short-term ROS generation can promote adipogenesis 
and lipid accumulation (Lee et al., 2009; Tormos et al., 2011; Wang et al., 2015; Jones 
IV et al., 2016; Hosios and Vander Heiden, 2018), and that stable high ROS and reduced 
antioxidant capacity are observed in obesity (Masschelin et al., 2020). Thus, the order 
of events, nutrients available, and the amount as well as intracellular localization and 
reason for ROS generation, might all decide the outcomes and effects observed on 





The reduced GSH production, and consequent increase in ROS generation when 
SLC7A10 function is inhibited, may also direct the metabolism away from oxidative 
phosphorylation and towards the increase in lipid accumulation we observe as a 
feedback mechanism to protect the cells against prolonged high ROS levels (Armstrong 
et al., 2004; Quijano et al., 2016). Previous studies have observed that high ROS levels 
in adipocytes can increase lipid synthesis (Jones IV et al., 2016). Homeostatic levels of 
ROS are thought to contribute to adipogenesis and healthy fat cells, while too low or too 
high levels contribute to adipocyte dysfunction (Rosen and Spiegelman, 2014). We 
observe increased ROS levels when inhibiting SLC7A10, which are decreased when 
ROS scavenger is added in an insulin-free condition. However, when insulin is present, 
the ROS scavenger failed to significantly reduce lipid accumulation in SLC7A10-
inhibited cells. These data suggest that insulin-dependent lipid accumulation might not 
be mediated via increased ROS, and that the lipid accumulation we observe upon 
SLC7A10 inhibition is at least partly independent of insulin and rather dependent on 
ROS, also consistent with the reduced insulin-stimulated glucose uptake upon SLC7A10 
impairment. Taken together, our data support a central role for altered mitochondrial 
respiration and ROS generation in lipid accumulation.  
Since serine is thought to be mainly taken up or synthesized from glucose or glycine 
(Amelio et al., 2014), one might hypothesize that serine biosynthesis is increased when 
SLC7A10 is impaired. Previous studies in cancer cells have revealed that serine 
starvation diverts intermediates from glycolysis to generation of pyruvate and serine 
biosynthesis to support cell proliferation (Ye et al., 2012; Maddocks et al., 2017). 
Surprisingly, we do not observe increased expression of genes involved in serine 
biosynthesis (data not shown), suggesting that serine deprivation in adipocytes due to 
SLC7A10 inhibition diverts carbons from taken up nutrients mainly to pyruvate 
production. The increase in pyruvate generation seen in cancer cells, from other sources 
than glucose, is found to be utilized by cells to increase oxidative phosphorylation 
(Chaneton et al., 2012), but since white adipocytes are specialized to store fat (Cohena 
and Spiegelmanb, 2016), synthesis of TAG may be prioritized. Such a prioritization of 
pyruvate for TAG synthesis independent of glucose contributes to explain the reduced 
insulin-stimulated glucose uptake we find when SLC7A10 is inhibited. 
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The reduced insulin-stimulated glucose uptake and the concomitant reduction in serine 
uptake upon SLC7A10 inhibition is consistent with a previous study showing that serine 
improves insulin sensitivity, and that lack of serine can cause cellular IR (Holm and 
Buschard, 2019). Thus, the SLC7A10 inhibitor-mediated reduction in serine uptake 
may, at least in part, explain the decreased insulin-dependent glucose uptake. The 
glucose uptake might also be reduced due to increased ROS and oxidative stress-
mediated carbonylation of GLUT4 (Masschelin et al., 2020), and to protect the cells 
against more glucose-fueling mitochondrial respiration which could generate even 
higher ROS levels (Stowe and Camara, 2009). A study in 3T3-L1 adipocytes found that 
exposure to transient ROS improved insulin sensitivity, while chronic ROS promoted 
IR (Ma et al., 2018). Furthermore, if most of the available glucose has to be utilized in 
the pentose phosphate pathway to generate NADPH for lipogenesis (Mullarky and 
Cantley, 2015) in response to SLC7A10 inhibition, the amount of energy substrates 
available for glycolysis and subsequently oxidative phosphorylation might be reduced. 
This prioritization of substrates for TAG synthesis might, at least in part, contribute to 
explain the reduced mitochondrial respiration we observe in SLC7A10-inhibited 
adipocytes.  
 
5.2 SLC7A10, 3-HIB and BCAAs in obesity and related diseases in vivo 
5.2.1 Associations with traits of metabolic syndrome 
Our human cohort data reveal inverse associations for adipocytic SLC7A10 expression 
and plasma 3-HIB concentrations with multiple traits of metabolic syndrome. In line 
with our data for SLC7A10, a previous study in SC adipocytes points to an inverse 
relationship between SLC7A10 mRNA expression in SC fat and BMI, HOMA-IR and 
circulating TAG levels (Small et al., 2011). In this study, Small et al. showed that a 
T2D-risk SNP in the genetic locus encoding the TF KLF14 caused alter expression of 
several adipocytic genes in trans, where SLC7A10 was the primary gene globally 
showing significantly reduced expression (Small et al., 2011). In a follow-up study, the 





hypertrophy and body fat distribution specifically in females (Small et al., 2018). These 
studies of the KLF14 locus partly linked to expression of adipose SLC7A10 mRNA 
indirectly support the associations we observe between SLC7A10 mRNA and adipocyte 
hypertrophy. However, a recent study using machine learning based technics to 
investigate adipocyte phenotypes in 4 large cohorts (n=1288), found no association 
between the KLF14 locus variants, or any other variants genome-wide, and adipocyte 
morphology phenotypes (Glastonbury et al., 2020). The authors discuss that this might 
be due to the low cohort size (n<50) used in the initial study (Glastonbury et al., 2020). 
To clarify the genetic influence on SLC7A10 expression and function, future studies may 
use genome editing approaches to modulate candidate variants in human adipocytes in 
vitro to determine phenotypic effects on adipocyte biology, as demonstrated for the FTO 
locus (Claussnitzer et al., 2015). Of note, although we here did not investigate sex-
specific regulation of SLC7A10, and how this might relate to cellular functions, some of 
our cohorts (e.g., SibPair) show around twice as high SLC7A10 mRNA in females 
compared to males with obesity (data not shown). It should also be noted that only one 
of the human primary cultures we used came from a man. Future studies should therefore 
investigate whether genetic variants influence SLC7A10 mRNA expression and function 
differently in men and women, and also explore the biological basis for and phenotypic 
consequences of the apparent sex-specific SLC7A10 expression.  
Regardless of genetic and sex-specific effects, we confirm a link between SLC7A10 and 
adipocyte hypertrophy in our human cohorts, consisting of both men and women, and 
our data from the overfeeding experiment in the Slc7a10b loss-of-function zebrafish 
indicates that the transporter is a causal factor regulating visceral fat cell size. A study 
in humans showed that overfeeding did not increase visceral fat cell size in subjects that 
were already insulin resistant, while people who were insulin sensitive developed 
significantly larger visceral fat cells (McLaughlin et al., 2016), which suggests that our 
mutant zebrafish were not insulin resistant before overfeeding. Thus, the negative effects 
of low adipocyte Slc7a10 levels on health might primarily occur when the nutrient 
supply is high. In people with obesity who are insulin sensitive, the expression levels of 
SLC7A10 is high, while people with obesity who are insulin resistant have low 
expression, indicating that SLC7A10 might be important in regulating whole body 
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insulin sensitivity. However, more in vivo research on causality and the order of cellular 
events after SLC7A10 impairment is warranted, and the specific mechanisms regulating 
the relationship between SLC7A10 and IR must be further investigated.  
There is some contradicting evidence in the obesity research field regarding the 
relationship between adipocyte hypertrophy and risk of obesity-related diseases, and this 
seems to be highly dependent on the adipose depot affected and on whether the subjects 
are insulin sensitive or resistant at the start of the study (McLaughlin et al., 2016). 
Supporting the commonly accepted relationship, we observed a strong positive 
correlation between fat cell size and HOMA-IR in the cohort where we also found a 
marked inverse correlation between SLC7A10 expression and SC adipocyte size (data 
not shown). A recent study found that SC hypertrophy was not related to HOMA-IR, 
while visceral adipocyte size significantly correlated positively with IR (Verboven et 
al., 2018). This study by Verboven and coworkers however contained few participants, 
which might indicate that effects on visceral adipocyte size are more readily detected 
and hence stronger compared to SAT. Yet, a previous report showed a strong positive 
correlation between adipocyte size in SC and OM adipose tissue in the context of IR 
(Klöting et al., 2010). In line with our results, this and other studies showed SC fat cell 
enlargement to be positively associated with both whole-body and SC adipocyte IR 
(Lundgren et al., 2007), and to be defined as a predictor of T2D risk (Weyer et al., 2001). 
In our human cohorts, we see highly consistent negative associations between SLC7A10 
expression in SAT, and both SC adipocyte cell size and HOMA-IR.  
3-HIB levels in plasma have previously been linked to future risk of T2D (Mardinoglu 
et al., 2018) and IR after gestational diabetes mellitus (Andersson-Hall et al., 2018). In 
our study, we find a clear pattern showing high 3-HIB concentrations in plasma of 
people with T2D, lower in hyperglycemia and lowest in normoglycemia. Plasma 3-HIB 
levels were also strongly correlated with several metabolic risk factors in our human 
cohorts and were strongly reduced one year after bariatric surgery in association with 
major fat loss and improved insulin sensitivity. Interestingly, we also observed an 
increase in plasma 3-HIB concentration 1 week after the weight loss surgery, which may 





and insulin sensitivity. Nonetheless, the data indicate that 3-HIB is a promising 
biomarker of future disease risk, at least under conditions of more stable nutrient supply. 
Moreover, we find an inverse association between SLC7A10 mRNA expression in SAT 
and plasma 3-HIB and BCAA levels in the MyoGlu cohort. To assess causality, it would 
be valuable to generate an adipocyte-specific SLC7A10 knockout model and measure 
the effect on circulating 3-HIB and BCAA levels, along with changes in body fat 
distribution, adipocyte morphology, IR, glucose tolerance and other disease risk 
markers. In such a model, it would also be relevant to examine the metabolic fate of 
administered radiolabeled BCAAs, such as on circulating and tissue levels of 
radiolabeled valine-derived 3-HIB using the approaches in the recent study by Neinast 
et al. (Neinast et al., 2019). 
 
5.2.2 Processes related to obesity and insulin resistance 
The levels of certain amino acids in plasma have been associated with IR and T2D 
(Yamada et al., 2015). Serine and glycine levels are inversely linked to metabolic 
syndrome, while the BCAAs (as well as glutamate) are strongly associated with disease 
risk (Felig, Marliss and Cahill, 1969; Yamada et al., 2015), consistent with our cohort 
data. In line with the reduced serine uptake and total GSH levels we observe when 
inhibiting SLC7A10 in adipocytes, previous studies in liver cells have found that 
inability to synthesize GSH is linked to increased IR (Guarino et al., 2003; Guarino and 
Macedo, 2006) and GSH supplementation to decrease IR (El-Hafidi et al., 2018). 
However, studies modulating GSH synthesis in adipocytes to investigate effects on 
thermogenesis and insulin sensitivity report mixed results (Kobayashi et al., 2009; 
Lettieri Barbato et al., 2015; Achari and Jain, 2017; Lu et al., 2017).  
We find increased FA uptake in both WAT and BAT after 3-HIB treatment, which is 
related to increased fat storage in adipocytes. However, a recent study reported that FA 
uptake into BAT is blunted in obesity (Saari et al., 2020), suggesting that the FA uptake 
we see upon addition of 3-HIB might facilitate a transient increase to compensate for 
increased nutrient availability. Importantly, increased ROS in adipocytes has also been 
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found prior to IR, and is suggested to be a possible cause and not only consequence of 
metabolic disease (Maslov et al., 2019), consistent with our data. In addition, reduced 
mitochondrial respiration in WAT has been described as a hallmark of obesity (mouse 
models) (Schöttl et al., 2015). In light of these recent studies and our SLC7A10 
overexpression data, increasing adipocyte SLC7A10 expression and function may be a 
possible treatment strategy in people with obesity or metabolic disease.  
Although we found that SLC7A10 correlates inversely with obesity and IR, we cannot 
rule out that the increased lipid accumulation upon SLC7A10 inhibition could be 
metabolically beneficial in early phases, prior to fat overload (Lee, Mottillo and 
Granneman, 2014; Ghaben and Scherer, 2019). Consistent with a transient beneficial 
effect is the upregulation of PPARγ expression which we find when inhibiting SLC7A10 
for 24 hours, together with increased expression of other adipogenic TFs. Genetic 
evidence supports that upregulation of PPARγ and a related increase in adipogenesis, at 
least in SC fat, supports metabolically beneficial functions in adipocytes that protect 
against IR and T2D (Claussnitzer et al., 2014). Such temporally beneficial effects might 
contribute to explain the observed down-regulation of genes involved in biological 
processes such as immune response in the zebrafish overfeeding study, in a reciprocal 
relationship between adipocyte metabolism and immune cell function (Macdougall et 
al., 2018). With a persistent increase in ROS, shown to promote adipocyte IR (Ma et al., 
2018), lipid accumulation may become a primary outlet for handling excess nutrients. 
While this may initially be protective, especially in SAT, over time the lipid storage may 
translate into excessive hypertrophy of individual adipocytes concomitant with 







In the present thesis, we provide new knowledge on SLC7A10 functions in adipocytes, 
and the role of this carrier and adipocyte amino acids metabolism in obesity and 
development of related diseases.  
Across several human cohorts we find a consistent inverse correlation between 
SLC7A10 mRNA and traits related to the metabolic syndrome. In experimental studies, 
we find that inhibition of SLC7A10 reduces serine uptake, manifesting in decreased 
production of the antioxidant GSH and increased ROS generation. Furthermore, 
SLC7A10 impairment decreases insulin-dependent glucose uptake and maximal 
mitochondrial respiratory capacity, in association with increased lipid accumulation in 
vitro and adipocyte hypertrophy in in vivo overfed Slc7a10b loss-of-function zebrafish. 
When persistent, these processes contribute to development of systemic IR and obesity-
related diseases. The sufficiency of altered SLC7A10 to exert marked effects on 
adipocyte metabolism was further supported by decreased ROS generation and 
increased mitochondrial respiratory capacity after SLC7A10 overexpression in 3T3-L1 
adipocytes.  
In our multiple human cohorts, circulating BCAA and 3-HIB levels are positively 
associated with metabolic risk traits and T2D. BCAA uptake and catabolism and 3-HIB 
efflux increase during human and mouse adipocyte differentiation in vitro, reflecting 
and possibly promoting lipid storage. Causal effects are supported by knockdown of the 
free 3-HIB generating enzyme Hibch, which leads to a reduction in both lipid 
accumulation and 3-HIB release from murine white and brown adipocytes. Furthermore, 
3-HIB treatment markedly modulates insulin-stimulated glucose uptake, FA uptake, 
mitochondrial respiration and ROS generation in both white and brown adipocytes, but 
for the two latter in the opposite direction between adipocyte subtypes, which may 
reflect as well as contribute to their different functional characteristics. Together, this 
indicates that 3-HIB may serve as an adipocyte-derived signaling molecule that 
contributes to communication between cells and/or tissues to modulate whole body 
glucose, fat and amino acid metabolism.  
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Our data indicate, that the increased lipid accumulation observed when SLC7A10 is 
inhibited might be fueled by a concomitant increase in adipocytic uptake of the amino 
acids aspartate, glutamate and BCAAs, associated with higher FA uptake, TCA cycle 
activity, glyceroneogenesis and lipogenesis. SLC7A10 mRNA expression levels in SAT 
in vivo are inversely correlated with the 3-HIB level in plasma, in line with our in vitro 
data showing increased HIBCH protein expression and 3-HIB release when SLC7A10 
function is impaired. This further strengthens the inverse association between SAT 
SLC7A10 expression and traits of metabolic syndrome, IR and T2D.  
Overall, we have identified SLC7A10 and 3-HIB as novel players in the regulation of 
adipocyte metabolism, and as potential therapeutic targets and biomarkers in the context 






7. Future perspectives 
In the present study we have uncovered novel functions of SLC7A10 and 3-HIB in the 
regulation of adipocyte metabolism. However, the research has raised new questions 
which remain to be addressed. 
Firstly, it would be interesting to investigate effects on adipocyte amino acid flux, GSH 
synthesis and metabolic processes when SLC7A10 is overexpressed, in combination 
with treatment with ROS-inducing compounds such as lipopolysaccharide (LPS), to 
explore to what extent SLC7A10 can protect against adipocyte dysfunction. Secondly, 
it would be valuable to delineate more details on the mechanisms by which SLC7A10 
and 3-HIB mediate their effects on adipocyte function, such as measuring the effect of 
SLC7A10 overexpression or 3-HIB stimulation on mitochondrial biogenesis. This could 
help reveal whether the observed changes in mitochondrial respiration could be, at least 
in part, caused by an increase in the number of mitochondria, or if they are caused by 
altered substrate availability or substrate-channeling towards oxidative phosphorylation.  
Importantly, we find a novel relationship between adipocytic SLC7A10, uptake of 
BCAAs and other amino acids not known to be transported by SLC7A10, and the release 
of 3-HIB from adipocytes. Here, the specific mechanistic pathways linking these 
features needs to be further explored, by for example performing radioactive or 
immunohistochemistry studies following the metabolic path of carbons from all the 
BCAAs when SLC7A10 is inhibited compared to control.  In addition, future studies 
should investigate the effect of Hibch KD on the uptake of leucine and isoleucine, and 
other relevant amino acids. 
Moreover, it would be of great interest to further explore the time-dependent metabolic 
effects of 3-HIB treatment in adipocytes. Also, the total contribution of adipocyte 3-HIB 
release to the total circulating concentration in vivo should be estimated, and examining 
whether this catabolite might participate in organ cross-talk, and how it might exert its 
communicative effects in both an autocrine, paracrine and endocrine manner, thereby 
influencing systemic IR and metabolic disease risk.  
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Furthermore, it appears relevant to investigate SLC7A10 in relation to aging, since 
serine has emerged as an important player in aging via epigenetic and metabolic 
mechanisms (Wu et al., 2020). In addition, determining whether SLC7A10 has sex-
specific effects would be valuable, in part because alleles close to KLF14, a “master 
regulator” of adipocyte gene expression including effects on SLC7A10, might influence 
T2D-risk through female-specific effects on fat distribution and adipocyte size (Small 
et al., 2018). Because the relationship between BCAAs and metabolic risk traits are 
found to be affected by sex differences (Newbern et al., 2014; Thalacker-Mercer et al., 
2014), this should be investigated in regard to adipocyte 3-HIB release as well.  
It would also be of interest to identify SNPs within the human SLC7A10 locus and 
investigate their possible impact on adipocyte metabolism as well as the mechanisms 
(e.g., enhancers and transcription factors) that control SLC7A10 expression. 
Additionally, generating a stable KD of SLC7A10 or editing relevant SNPs in human 
immortalized adipocytes by genome editing in vitro would be valuable tools to further 
explore SLC7A10’s role in adipocytes, obesity and IR.  
In our overfeeding study, we utilized zebrafish with a global Slc7a10b loss-of-function 
mutation, and we collected RNA, DNA and proteins from VAT at the end of the study. 
Due to few zebrafish-specific antibodies available, we did not measure protein 
expression. It would be useful to develop antibodies for the zebrafish proteins of interest 
and perform proteomics, comparing WT and loss-of-function, and/or perform similar 
experiments in other animal models. Because Slc7a10 is also expressed in the brain, it 
would have been of great interest to conduct another overfeeding experiment in 
zebrafish or mice with an adipocyte-specific Slc7a10 knockout. Another possibility 
would be to inject the SLC7A10 inhibitor LU into mouse peripheral tissues, since it is 
not able to cross the blood brain barrier, to investigate effects on fat storage and whole-
body insulin sensitivity.  
While impairment of SLC7A10 exerts negative effects on adipocyte metabolism, 
overexpressing or amplifying the transporter functions in vivo may cause improvements 





positive regulators of SLC7A10 could provide additional direct targets for modulating 
adipocyte dysfunction, with the view to develop new strategies to improve insulin 
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